Hiroshi Yamazaki

List of Publications by Citations

501 papers	12,667 citations	54 h-index	86 g-index
542 ext. papers	13,807 ext. citations	3 avg, IF	6.27 L-index

#	Paper	IF	Citations
501	Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. *Carcinogenesis*, **1992**, 13, 1789-94	4.6	335
500	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. *Archives of Biochemistry and Biophysics*, **1997**, 346, 161-9	4.1	249
499	Activation and detoxication of aflatoxin B1. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **1998**, 402, 121-8	3.3	216
498	Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. *Protein Expression and Purification*, **2002**, 24, 329-37	2	201
497	Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population. *Gastroenterology*, **2016**, 150, 1171-1182	13.3	195
496	Oxidation of aflatoxin B1 by bacterial recombinant human cytochrome P450 enzymes. *Chemical Research in Toxicology*, **1995**, 8, 218-25	4	193
495	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. *Archives of Toxicology*, **1999**, 73, 65-70	5.8	188
494	Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1. *Chemical Research in Toxicology*, **1998**, 11, 1048-56	4	182
493	Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. *Chemical Research in Toxicology*, **1998**, 11, 659-65	4	158
492	Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. *Carcinogenesis*, **2004**, 25, 2451-8	4.6	151
491	Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. *British Journal of Clinical Pharmacology*, **2000**, 49, 244-53	3.8	148
490	Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans. *Archives of Toxicology*, **1997**, 71, 401-8	5.8	146
489	Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. *Biochemical Pharmacology*, **1998**, 56, 243-51	6	139
488	Lack of electron transfer from cytochrome b5 in stimulation of catalytic activities of cytochrome P450 3A4. Characterization of a reconstituted cytochrome P450 3A4/NADPH-cytochrome P450 reductase system and studies with apo-cytochrome b5. *Journal of Biological Chemistry*, **1996**, 271, 27438-44	5.4	136
487	Expression of cytochrome P450 3A5 in Escherichia coli: effects of 5O modification, purification, spectral characterization, reconstitution conditions, and catalytic activities. *Archives of Biochemistry and Biophysics*, **1995**, 317, 374-84	4.1	133
486	Roles of divalent metal ions in oxidations catalyzed by recombinant cytochrome P450 3A4 and replacement of NADPH--cytochrome P450 reductase with other flavoproteins, ferredoxin, and oxygen surrogates. *Biochemistry*, **1995**, 34, 8380-9	3.2	129
485	Roles of cytochrome b5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes. *Archives of Biochemistry and Biophysics*, **1996**, 325, 174-82	4.1	125

484	Reconstitution of recombinant cytochrome P450 2C10(2C9) and comparison with cytochrome P450 3A4 and other forms: effects of cytochrome P450-P450 and cytochrome P450-b5 interactions. *Archives of Biochemistry and Biophysics*, **1997**, 342, 329-37	4.1	120
483	Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers. *Biochemical Pharmacology*, **1997**, 54, 1195-203	6	119
482	Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4Ohydroxylation activities in livers of Japanese and Caucasian populations. *Pharmacogenetics and Genomics*, **1997**, 7, 103-13		116
481	A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur. *Pharmacogenetics and Genomics*, **2002**, 12, 299-306		110
480	Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. *Clinical Pharmacology and Therapeutics*, **2001**, 69, 72-8	6.1	109
479	Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. *Biochemical Pharmacology*, **2007**, 73, 2020-6	6	106
478	Molecular cloning of a novel human collectin from liver (CL-L1). *Journal of Biological Chemistry*, **1999**, 274, 13681-9	5.4	102
477	Structure-function relationships of inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2C9, and 3A4 by 33 flavonoid derivatives. *Chemical Research in Toxicology*, **2010**, 23, 1921-35	4	99
476	Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. *Biochemical Pharmacology*, **1994**, 47, 727-35	6	96
475	Macaque cytochromes P450: nomenclature, transcript, gene, genomic structure, and function. *Drug Metabolism Reviews*, **2011**, 43, 346-61	7	90
474	Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population. *British Journal of Clinical Pharmacology*, **2008**, 65, 437-9	3.8	90
473	7-Ethoxycoumarin O-deethylation catalyzed by cytochromes P450 1A2 and 2E1 in human liver microsomes. *Biochemical Pharmacology*, **1996**, 51, 313-9	6	85
472	Participation of rat liver cytochrome P450 2E1 in the activation of N-nitrosodimethylamine and N-nitrosodiethylamine to products genotoxic in an acetyltransferase-overexpressing Salmonella typhimurium strain (NM2009). *Carcinogenesis*, **1992**, 13, 979-85	4.6	84
471	Stimulation of cytochrome P450 reactions by apo-cytochrome b5: evidence against transfer of heme from cytochrome P450 3A4 to apo-cytochrome b5 or heme oxygenase. *Journal of Biological Chemistry*, **2001**, 276, 30885-91	5.4	83
470	Nicotine metabolism and CYP2A6 allele frequencies in Koreans. *Pharmacogenetics and Genomics*, **2001**, 11, 317-23		83
469	Identification of a novel polymorphic enhancer of the human CYP3A4 gene. *Molecular Pharmacology*, **2004**, 65, 326-34	4.3	82
468	Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxicity to HepG2 cells. *Drug Metabolism and Disposition*, **2002**, 30, 155-60	4	75
467	Two naturally occurring terpenes, dehydrocostuslactone and costunolide, decrease intracellular GSH content and inhibit STAT3 activation. *PLoS ONE*, **2011**, 6, e20174	3.7	75

466	Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells. *Life Sciences*, **2001**, 70, 471-82	6.8	74
465	Regioselective hydroxylation of steroid hormones by human cytochromes P450. *Drug Metabolism Reviews*, **2015**, 47, 89-110	7	70
464	Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5. *Current Drug Metabolism*, **2008**, 9, 20-33	3.5	69
463	Prediction of in vivo drug clearance from in vitro data. II: potential inter-ethnic differences. *Xenobiotica*, **2006**, 36, 499-513	2	67
462	Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. *European Journal of Pharmaceutical Sciences*, **2001**, 12, 505-13	5.1	67
461	Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4. *Pharmaceutical Research*, **2000**, 17, 1189-97	4.5	67
460	Drug interactions between nine antifungal agents and drugs metabolized by human cytochromes P450. *Current Drug Metabolism*, **2014**, 15, 651-79	3.5	67
459	Distinct ontogenic and regional expressions of newly identified Cajal-Retzius cell-specific genes during neocorticogenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 14509-14	11.5	66
458	Requirements for cytochrome b5 in the oxidation of 7-ethoxycoumarin, chlorzoxazone, aniline, and N-nitrosodimethylamine by recombinant cytochrome P450 2E1 and by human liver microsomes. *Biochemical Pharmacology*, **1996**, 52, 301-9	6	66
457	Development of high sensitive umu test system: rapid detection of genotoxicity of promutagenic aromatic amines by Salmonella typhimurium strain NM2009 possessing high O-acetyltransferase activity. *Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology*, **1995**, 334, 145-56		65
456	Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype. *Journal of Infectious Diseases*, **2014**, 209, 1941-8	7	62
455	Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9). *Pharmacogenetics and Genomics*, **2003**, 13, 689-95		62
454	Recombinant human cytochrome P450 1A2 and an N-terminal-truncated form: construction, purification, aggregation properties, and interactions with flavodoxin, ferredoxin, and NADPH-cytochrome P450 reductase. *Archives of Biochemistry and Biophysics*, **1996**, 327, 11-9	4.1	61
453	Human cytochrome P450 2A13 efficiently metabolizes chemicals in air pollutants: naphthalene, styrene, and toluene. *Chemical Research in Toxicology*, **2008**, 21, 720-5	4	60
452	Involvement of Cytochrome P450, Glutathione S-Transferase, and Epoxide Hydrolase in the Metabolism of Aflatoxin B 1 and Relevance to Risk of Human Liver Cancer. *Environmental Health Perspectives*, **1996**, 104, 557	8.4	56
451	CYP2A13 expressed in human bladder metabolically activates 4-aminobiphenyl. *International Journal of Cancer*, **2006**, 119, 2520-6	7.5	56
450	Oral L-carnitine supplementation increases trimethylamine-N-oxide but reduces markers of vascular injury in hemodialysis patients. *Journal of Cardiovascular Pharmacology*, **2015**, 65, 289-95	3.1	55
449	CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes. *Journal of Toxicological Sciences*, **2013**, 38, 349-54	1.9	55

448	Transient trimethylaminuria related to menstruation. *BMC Medical Genetics*, **2007**, 8, 2	2.1	54
447	Highly sensitive umu test system for the detection of mutagenic nitroarenes in Salmonella typhimurium NM3009 having high O-acetyltransferase and nitroreductase activities. *Environmental and Molecular Mutagenesis*, **1993**, 21, 357-64	3.2	53
446	Aflatoxin B1 8,9-epoxide hydrolysis in the presence of rat and human epoxide hydrolase. *Chemical Research in Toxicology*, **1997**, 10, 672-6	4	52
445	Different mechanisms for inhibition of human cytochromes P450 1A1, 1A2, and 1B1 by polycyclic aromatic inhibitors. *Chemical Research in Toxicology*, **2007**, 20, 489-96	4	52
444	Survey of variants of human flavin-containing monooxygenase 3 (FMO3) and their drug oxidation activities. *Biochemical Pharmacology*, **2013**, 85, 1588-93	6	51
443	Evaluation of drug toxicity with hepatocytes cultured in a micro-space cell culture system. *Journal of Bioscience and Bioengineering*, **2011**, 111, 78-84	3.3	51
442	Genetic variants of CYP3A4 and CYP3A5 in cynomolgus and rhesus macaques. *Drug Metabolism and Disposition*, **2010**, 38, 209-14	4	51
441	Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: lack of co-regulation of the expression of CYP3A in Japanese livers. *Xenobiotica*, **2005**, 35, 69-83	2	51
440	Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes. *Xenobiotica*, **1998**, 28, 103-15	2	51
439	Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution. *Current Drug Metabolism*, **2010**, 11, 678-85	3.5	50
438	Bioactivation of diesel exhaust particle extracts and their major nitrated polycyclic aromatic hydrocarbon components, 1-nitropyrene and dinitropyrenes, by human cytochromes P450 1A1, 1A2, and 1B1. *Mutation Research - Genetic Toxicology and Environmental Mutagenesis*, **2000**, 472, 129-38	3	50
437	Characterization of (+/-)-bufuralol hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for CYP2D6. *Pharmacogenetics and Genomics*, **2001**, 11, 143-56		50
436	High rates of substrate hydroxylation by human cytochrome P450 3A4 in reconstituted membranous vesicles: influence of membrane charge. *Biochemical and Biophysical Research Communications*, **1996**, 221, 318-22	3.4	50
435	Heterotropic cooperativity in oxidation mediated by cytochrome p450. *Current Drug Metabolism*, **2008**, 9, 453-62	3.5	49
434	Effect of genetic variants of the human flavin-containing monooxygenase 3 on N- and S-oxygenation activities. *Drug Metabolism and Disposition*, **2007**, 35, 328-30	4	49
433	Effects of the dietary supplements, activated charcoal and copper chlorophyllin, on urinary excretion of trimethylamine in Japanese trimethylaminuria patients. *Life Sciences*, **2004**, 74, 2739-47	6.8	49
432	CYP2A6 genetic polymorphisms and liver microsomal coumarin and nicotine oxidation activities in Japanese and Caucasians. *Archives of Toxicology*, **2000**, 73, 532-9	5.8	49
431	Immunochemical detection of cytochrome P450 enzymes in liver microsomes of 27 cynomolgus monkeys. *Journal of Pharmacology and Experimental Therapeutics*, **2011**, 339, 654-61	4.7	48

430	Procarcinogen activation by cytochrome P450 3A4 and 3A5 expressed in Escherichia coli and by human liver microsomes. *Carcinogenesis*, **1995**, 16, 2167-70	4.6	48
429	Pretreatment with 8-methoxypsoralen, a potent human CYP2A6 inhibitor, strongly inhibits lung tumorigenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in female A/J mice. *Cancer Research*, **2003**, 63, 7581-3	10.1	48
428	Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7. *Biochemical Pharmacology*, **2003**, 66, 2333-40	6	47
427	CYP2A6 gene deletion reduces oral cancer risk in betel quid chewers in Sri Lanka. *Carcinogenesis*, **2002**, 23, 595-8	4.6	47
426	Assignment of the human cytochrome P-450 nifedipine oxidase gene (CYP3A4) to chromosome 7 at band q22.1 by fluorescence in situ hybridization. *Japanese Journal of Human Genetics*, **1992**, 37, 133-8		47
425	Utility of non-human primates in drug development: Comparison of non-human primate and human drug-metabolizing cytochrome P450 enzymes. *Biochemical Pharmacology*, **2016**, 121, 1-7	6	47
424	Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles. *British Journal of Clinical Pharmacology*, **2010**, 69, 593-7	3.8	45
423	Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes. *Xenobiotica*, **2009**, 39, 795-802	2	45
422	Evaluation of approach to predict the contribution of multiple cytochrome P450s in drug metabolism using relative activity factor: effects of the differences in expression levels of NADPH-cytochrome P450 reductase and cytochrome b(5) in the expression system and the differences in the marker activities. *Journal of Pharmaceutical Sciences*, **2002**, 91, 952-63	3.9	45
421	Metabolic activation of polycyclic aromatic hydrocarbons and aryl and heterocyclic amines by human cytochromes P450 2A13 and 2A6. *Chemical Research in Toxicology*, **2013**, 26, 529-37	4	42
420	CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects. *Drug Metabolism and Pharmacokinetics*, **2004**, 19, 120-9	2.2	42
419	A new PCR-based assay amplifies the E6-E7 genes of most mucosal human papillomaviruses (HPV). *Virus Research*, **2000**, 67, 127-39	6.4	41
418	Highly sensitive high-performance liquid chromatographic assay for coumarin 7-hydroxylation and 7-ethoxycoumarin O-deethylation by human liver cytochrome P450 enzymes. *Biomedical Applications*, **1999**, 721, 13-9		41
417	Catalytic roles of rat and human cytochrome P450 2A enzymes in testosterone 7 alpha- and coumarin 7-hydroxylations. *Biochemical Pharmacology*, **1994**, 48, 1524-7	6	41
416	Human liver microsomal cytochrome P450 3A enzymes involved in thalidomide 5-hydroxylation and formation of a glutathione conjugate. *Chemical Research in Toxicology*, **2010**, 23, 1018-24	4	40
415	Pharmacokinetics of antifungal agent micafungin in critically ill patients receiving continuous hemodialysis filtration. *Yakugaku Zasshi*, **2007**, 127, 897-901	0	40
414	A population phenotyping study of three drug-metabolizing enzymes in Kyushu, Japan, with use of the caffeine test. *Clinical Pharmacology and Therapeutics*, **2002**, 72, 200-8	6.1	40
413	Functional polymer-dependent 3D culture accelerates the differentiation of HepaRG cells into mature hepatocytes. *Hepatology Research*, **2016**, 46, 1045-57	5.1	39

412	In vivo formation of dihydroxylated and glutathione conjugate metabolites derived from thalidomide and 5-Hydroxythalidomide in humanized TK-NOG mice. *Chemical Research in Toxicology* , **2012**, 25, 274-6	4	39
411	CYP1D1, pseudogenized in human, is expressed and encodes a functional drug-metabolizing enzyme in cynomolgus monkey. *Biochemical Pharmacology*, **2011**, 81, 442-50	6	39
410	Mechanisms of chemopreventive effects of 8-methoxypsoralen against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung adenomas. *Carcinogenesis*, **2005**, 26, 1947-55	4.6	39
409	Hepatocyte nuclear factor-1alpha is a causal factor responsible for interindividual differences in the expression of UDP-glucuronosyltransferase 2B7 mRNA in human livers. *Drug Metabolism and Disposition*, **2002**, 30, 613-5	4	39
408	Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1Ghydroxylation. *Drug Metabolism and Disposition*, **2011**, 39, 757-62	4	38
407	Human blood concentrations of cotinine, a biomonitoring marker for tobacco smoke, extrapolated from nicotine metabolism in rats and humans and physiologically based pharmacokinetic modeling. *International Journal of Environmental Research and Public Health*, **2010**, 7, 3406-21	4.6	37
406	Drug interactions of thalidomide with midazolam and cyclosporine A: heterotropic cooperativity of human cytochrome P450 3A5. *Drug Metabolism and Disposition*, **2009**, 37, 18-23	4	37
405	Immunoglobulin-A and -G responses against virus-like particles (VLP) of human papillomavirus type 16 in women with cervical cancer and cervical intra-epithelial lesions. *International Journal of Cancer* , **1998**, 75, 529-35	7.5	37
404	In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais. *Drug Metabolism and Pharmacokinetics*, **2006**, 21, 475-84	2.2	37
403	Mutagenic activation of 3-methoxy-4-aminoazobenzene by mouse renal cytochrome P450 CYP4B1: cloning and characterization of mouse CYP4B1. *Archives of Biochemistry and Biophysics*, **1995**, 321, 255-62	4.1	37
402	Mutagenic activation of carcinogenic N-nitrosopropylamines by rat liver: evidence for a cytochrome P-450 dependent reaction. *Carcinogenesis*, **1985**, 6, 415-20	4.6	37
401	Utilization of estimated physicochemical properties as an integrated part of predicting hepatic clearance in the early drug-discovery stage: Impact of plasma and microsomal binding. *Xenobiotica*, **2009**, 39, 227-35	2	36
400	Cytochrome P450-dependent drug oxidation activity of liver microsomes from Microminipigs, a possible new animal model for humans in non-clinical studies. *Drug Metabolism and Pharmacokinetics*, **2009**, 24, 404-8	2.2	36
399	Novel Marmoset Cytochrome P450 2C19 in Livers Efficiently Metabolizes Human P450 2C9 and 2C19 Substrates, S-Warfarin, Tolbutamide, Flurbiprofen, and Omeprazole. *Drug Metabolism and Disposition*, **2015**, 43, 1408-16	4	35
398	Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans. *Xenobiotica*, **2014**, 44, 242-53	2	35
397	In vivo drug interactions of the teratogen thalidomide with midazolam: heterotropic cooperativity of human cytochrome P450 in humanized TK-NOG mice. *Chemical Research in Toxicology*, **2013**, 26, 486-9	4	35
396	Cynomolgus monkey CYP2D44 newly identified in liver, metabolizes bufuralol, and dextromethorphan. *Drug Metabolism and Disposition*, **2010**, 38, 1486-92	4	35
395	Reverse type I binding spectra of human cytochrome P450 1B1 induced by flavonoid, stilbene, pyrene, naphthalene, phenanthrene, and biphenyl derivatives that inhibit catalytic activity: a structure-function relationship study. *Chemical Research in Toxicology*, **2009**, 22, 1325-33	4	35

394	Inter-individual variation of cytochrome P4502J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations. *Xenobiotica*, **2006**, 36, 1201-9	2	34
393	Hybrid capture-II and LCR-E7 PCR assays for HPV typing in cervical cytologic samples. *International Journal of Cancer*, **2001**, 94, 222-7	7.5	34
392	Lung tumorigenesis promoted by anti-apoptotic effects of cotinine, a nicotine metabolite through activation of PI3K/Akt pathway. *Journal of Toxicological Sciences*, **2012**, 37, 555-63	1.9	33
391	Oxidation of endobiotics mediated by xenobiotic-metabolizing forms of human cytochrome. *Current Drug Metabolism*, **2009**, 10, 700-12	3.5	33
390	A new Salmonella typhimurium NM5004 strain expressing rat glutathione S-transferase 5-5: use in detection of genotoxicity of dihaloalkanes using an SOS/umu test system. *Carcinogenesis*, **1996**, 17, 297-302	4.6	33
389	Roles of different forms of cytochrome P450 in the activation of the promutagen 6-aminochrysene to genotoxic metabolites in human liver microsomes. *Carcinogenesis*, **1993**, 14, 1271-8	4.6	33
388	The evaluation of genotoxic activities of disinfectants and their metabolites by umu test. *Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis*, **1988**, 209, 155-60		33
387	Drug oxygenation activities mediated by liver microsomal flavin-containing monooxygenases 1 and 3 in humans, monkeys, rats, and minipigs. *Biochemical Pharmacology*, **2014**, 90, 159-65	6	32
386	Catalytic activities of cytochrome P450 enzymes and UDP-glucuronosyltransferases involved in drug metabolism in rat everted sacs and intestinal microsomes. *Xenobiotica*, **2003**, 33, 43-55	2	32
385	Variation in coumarin 7-hydroxylase activity associated with genetic polymorphism of cytochrome P450 2A6 and the body status of iron stores in adult Thai males and females. *Pharmacogenetics and Genomics*, **2002**, 12, 241-9		32
384	Approach for in vivo protein binding of 5-n-butyl-pyrazolo[1,5-a]pyrimidine bioactivated in chimeric mice with humanized liver by two-dimensional electrophoresis with accelerator mass spectrometry. *Chemical Research in Toxicology*, **2010**, 23, 152-8	4	31
383	Interaction of polycyclic aromatic hydrocarbons with human cytochrome P450 1B1 in inhibiting catalytic activity. *Chemical Research in Toxicology*, **2008**, 21, 2313-23	4	31
382	Stop codon mutations in the flavin-containing monooxygenase 3 (FMO3) gene responsible for trimethylaminuria in a Japanese population. *Molecular Genetics and Metabolism*, **2007**, 90, 58-63	3.7	31
381	Activation and inactivation of carcinogenic dihaloalkanes and other compounds by glutathione S-transferase 5-5 in Salmonella typhimurium tester strain NM5004. *Chemical Research in Toxicology*, **1996**, 9, 333-40	4	31
380	Thalidomide-induced limb abnormalities in a humanized CYP3A mouse model. *Scientific Reports*, **2016**, 6, 21419	4.9	31
379	CYP2C19 polymorphisms account for inter-individual variability of drug metabolism in cynomolgus macaques. *Biochemical Pharmacology*, **2014**, 91, 242-8	6	30
378	Genetic polymorphism of the flavin-containing monooxygenase 3 (FMO3) associated with trimethylaminuria (fish odor syndrome): observations from Japanese patients. *Current Drug Metabolism*, **2007**, 8, 487-91	3.5	30
377	High prevalence of cytochrome P450 2A6*1A alleles in a black African population of Ghana. *European Journal of Clinical Pharmacology*, **2005**, 60, 855-7	2.8	30

376	Plasma and Hepatic Concentrations of Chemicals after Virtual Oral Administrations Extrapolated Using Rat Plasma Data and Simple Physiologically Based Pharmacokinetic Models. *Chemical Research in Toxicology*, **2019**, 32, 211-218	4	30
375	Combining Chimeric Mice with Humanized Liver, Mass Spectrometry, and Physiologically-Based Pharmacokinetic Modeling in Toxicology. *Chemical Research in Toxicology*, **2016**, 29, 1903-1911	4	29
374	Human plasma concentrations of cytochrome P450 probe cocktails extrapolated from pharmacokinetics in mice transplanted with human hepatocytes and from pharmacokinetics in common marmosets using physiologically based pharmacokinetic modeling. *Xenobiotica*, **2016**, 46, 1049-1055	2	29
373	Binding of diverse environmental chemicals with human cytochromes P450 2A13, 2A6, and 1B1 and enzyme inhibition. *Chemical Research in Toxicology*, **2013**, 26, 517-28	4	29
372	Pitavastatin as an in vivo probe for studying hepatic organic anion transporting polypeptide-mediated drug-drug interactions in cynomolgus monkeys. *Drug Metabolism and Disposition*, **2013**, 41, 1875-82	4	29
371	Blood concentrations of acrylonitrile in humans after oral administration extrapolated from in vivo rat pharmacokinetics, in vitro human metabolism, and physiologically based pharmacokinetic modeling. *Regulatory Toxicology and Pharmacology*, **2010**, 58, 252-8	3.4	29
370	Two novel haplotypes of CYP2D6 gene in a Japanese population. *Drug Metabolism and Pharmacokinetics*, **2003**, 18, 269-71	2.2	29
369	Uridine diphosphate sugar-selective conjugation of an aldose reductase inhibitor (AS-3201) by UDP-glucuronosyltransferase 2B subfamily in human liver microsomes. *Biochemical Pharmacology*, **2004**, 67, 1269-78	6	29
368	Induction of cytochrome P450 1B1 in lung, liver and kidney of rats exposed to diesel exhaust. *Carcinogenesis*, **2001**, 22, 2033-8	4.6	29
367	Comparison of cytochrome P450 2D6 and variants in terms of drug oxidation rates and substrate inhibition. *Current Drug Metabolism*, **2011**, 12, 412-35	3.5	28
366	Microminipig, a non-rodent experimental animal optimized for life science research: in vivo proarrhythmia models of drug-induced long QT syndrome: development of chronic atrioventricular block model of microminipig. *Journal of Pharmacological Sciences*, **2011**, 115, 122-6	3.7	28
365	Simultaneous pharmacokinetics assessment of caffeine, warfarin, omeprazole, metoprolol, and midazolam intravenously or orally administered to Microminipigs. *Journal of Toxicological Sciences*, **2012**, 37, 1157-64	1.9	28
364	Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans. *Drug Metabolism and Disposition*, **2005**, 33, 1361-6	4	28
363	Benzydamine N-oxygenation as an index for flavin-containing monooxygenase activity and benzydamine N-demethylation by cytochrome P450 enzymes in liver microsomes from rats, dogs, monkeys, and humans. *Drug Metabolism and Pharmacokinetics*, **2015**, 30, 64-9	2.2	27
362	Stem cell self-renewal factors Bmi1 and HMGA2 in head and neck squamous cell carcinoma: clues for diagnosis. *Laboratory Investigation*, **2013**, 93, 1331-8	5.9	27
361	In vivo formation of a glutathione conjugate derived from thalidomide in humanized uPA-NOG mice. *Chemical Research in Toxicology*, **2011**, 24, 287-9	4	27
360	Individual differences in pharmacokinetics and pharmacodynamics of anesthetic agent propofol with regard to CYP2B6 and UGT1A9 genotype and patient age. *Drug Metabolism and Pharmacokinetics*, **2011**, 26, 532-7	2.2	27
359	Molecular evolution and balancing selection in the flavin-containing monooxygenase 3 gene (FMO3). *Pharmacogenetics and Genomics*, **2007**, 17, 827-39	1.9	27

358	Two novel single nucleotide polymorphisms (SNPs) of the FMO3 gene in Japanese. *Drug Metabolism and Pharmacokinetics*, **2003**, 18, 333-5	2.2	27
357	Twenty one novel single nucleotide polymorphisms (SNPs) of the CYP2A6 gene in Japanese and Caucasians. *Drug Metabolism and Pharmacokinetics*, **2002**, 17, 482-7	2.2	27
356	Qualitative de novo analysis of full length cDNA and quantitative analysis of gene expression for common marmoset (Callithrix jacchus) transcriptomes using parallel long-read technology and short-read sequencing. *PLoS ONE*, **2014**, 9, e100936	3.7	27
355	Human cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide. *Chemical Research in Toxicology*, **2014**, 27, 147-56	4	26
354	Plasma concentrations of melengestrol acetate in humans extrapolated from the pharmacokinetics established in in vivo experiments with rats and chimeric mice with humanized liver and physiologically based pharmacokinetic modeling. *Regulatory Toxicology and Pharmacology*, **2013**, 65, 316-24	3.4	26
353	The Dihydroxy Metabolite of the Teratogen Thalidomide Causes Oxidative DNA Damage. *Chemical Research in Toxicology*, **2017**, 30, 1622-1628	4	26
352	Two novel CYP2D6*10 haplotypes as possible causes of a poor metabolic phenotype in Japanese. *Drug Metabolism and Disposition*, **2009**, 37, 699-701	4	26
351	Human cytochrome P450 1A2 involvement in the formation of reactive metabolites from a species-specific hepatotoxic pyrazolopyrimidine derivative, 5-n-butyl-7-(3,4,5-trimethoxybenzoylamino)pyrazolo[1,5-a]pyrimidine. *Chemical Research in Toxicology*, **2009**, 22, 323-31	4	26
350	Cooperativity of alpha-naphthoflavone in cytochrome P450 3A-dependent drug oxidation activities in hepatic and intestinal microsomes from mouse and human. *Xenobiotica*, **2001**, 31, 265-75	2	26
349	Biomonitoring of urinary cotinine concentrations associated with plasma levels of nicotine metabolites after daily cigarette smoking in a male Japanese population. *International Journal of Environmental Research and Public Health*, **2010**, 7, 2953-64	4.6	25
348	Establishment of ten strains of genetically engineered Salmonella typhimurium TA1538 each co-expressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase sensitive to various promutagens. *Mutation Research - Genetic Toxicology and Environmental Mutagenesis*, **2004**, 562, 151-62	3	25
347	Phospholipase D activity of cytochrome P450 in human liver endoplasmic reticulum. *Archives of Biochemistry and Biophysics*, **1999**, 367, 81-8	4.1	25
346	Marmoset cytochrome P450 2D8 in livers and small intestines metabolizes typical human P450 2D6 substrates, metoprolol, bufuralol and dextromethorphan. *Xenobiotica*, **2015**, 45, 766-72	2	24
345	Thalidomide increases human hepatic cytochrome P450 3A enzymes by direct activation of the pregnane X receptor. *Chemical Research in Toxicology*, **2014**, 27, 304-308	4	24
344	Molecular and functional characterization of flavin-containing monooxygenases in cynomolgus macaque. *Biochemical Pharmacology*, **2013**, 85, 1837-47	6	24
343	Alprazolam as an in vivo probe for studying induction of CYP3A in cynomolgus monkeys. *Drug Metabolism and Disposition*, **2010**, 38, 1806-13	4	24
342	A novel CYP2A26 identified in cynomolgus monkey liver metabolizes coumarin. *Xenobiotica*, **2010**, 40, 621-9	2	24
341	Spectral modification and catalytic inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2A6, and 2A13 by four chemopreventive organoselenium compounds. *Chemical Research in Toxicology*, **2011**, 24, 1327-37	4	24

340	Rat cytochrome P450 2C11 in liver microsomes involved in oxidation of anesthetic agent propofol and deactivated by prior treatment with propofol. *Drug Metabolism and Disposition*, **2006**, 34, 1803-5	4	24
339	Inhibitory effect of organic solvents on the mutagenicity of N-nitrosodialkylamines in Salmonella. *Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis*, **1985**, 142, 153-8		24
338	Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus). *Xenobiotica*, **2016**, 46, 163-8	2	23
337	Human biofluid concentrations of mono(2-ethylhexyl)phthalate extrapolated from pharmacokinetics in chimeric mice with humanized liver administered with di(2-ethylhexyl)phthalate and physiologically based pharmacokinetic modeling. *Environmental Toxicology and Pharmacology*, **2015**, 39, 1067-73	5.8	23
336	Activation and deactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by cytochrome P450 enzymes and flavin-containing monooxygenases in common marmosets (Callithrix jacchus). *Drug Metabolism and Disposition*, **2015**, 43, 735-42	4	23
335	Simulation of human plasma concentration-time profiles of the partial glucokinase activator PF-04937319 and its disproportionate N-demethylated metabolite using humanized chimeric mice and semi-physiological pharmacokinetic modeling. *Xenobiotica*, **2017**, 47, 382-393	2	23
334	Age-related pharmacokinetic changes of acetaminophen, antipyrine, diazepam, diphenhydramine, and ofloxacin in male cynomolgus monkeys and beagle dogs. *Xenobiotica*, **2014**, 44, 893-901	2	23
333	Limited effects of frequent CYP2D6*36-*10 tandem duplication allele on in vivo dextromethorphan metabolism in a Japanese population. *European Journal of Clinical Pharmacology*, **2010**, 66, 1065-8	2.8	23
332	Azithromycin Can Prolong QT Interval and Suppress Ventricular Contraction, but Will Not Induce Torsade de Pointes. *Cardiovascular Toxicology*, **2015**, 15, 232-40	3.4	22
331	Simulation of Human Plasma Concentrations of Thalidomide and Primary 5-Hydroxylated Metabolites Explored with Pharmacokinetic Data in Humanized TK-NOG Mice. *Chemical Research in Toxicology*, **2015**, 28, 2088-90	4	22
330	Slow R-warfarin 7-hydroxylation mediated by P450 2C19 genetic variants in cynomolgus monkeys in vivo. *Biochemical Pharmacology*, **2015**, 95, 110-4	6	22
329	Developmental variations in metabolic capacity of flavin-containing mono-oxygenase 3 in childhood. *British Journal of Clinical Pharmacology*, **2011**, 71, 585-91	3.8	22
328	Comparison of cytochrome P450 3A enzymes in cynomolgus monkeys and humans. *Drug Metabolism and Pharmacokinetics*, **2010**, 25, 388-91	2.2	22
327	Role of human N-acetyltransferases, NAT1 or NAT2, in genotoxicity of nitroarenes and aromatic amines in Salmonella typhimurium NM6001 and NM6002. *Carcinogenesis*, **1999**, 20, 1079-83	4.6	22
326	Evaluation of 23 lots of commercially available cryopreserved hepatocytes for induction assays of human cytochromes P450. *Drug Metabolism and Disposition*, **2014**, 42, 867-71	4	21
325	Stereoselectivity of human cytochrome p450 in metabolic and inhibitory activities. *Current Drug Metabolism*, **2011**, 12, 549-69	3.5	21
324	Inter-individual variation in flavin-containing monooxygenase 3 in livers from Japanese: correlation with hepatic transcription factors. *Drug Metabolism and Pharmacokinetics*, **2009**, 24, 218-25	2.2	21
323	Differential roles of cytochromes P450 2D1, 2C11, and 1A1/2 in the hydroxylation of bufuralol by rat liver microsomes. *Biochemical Pharmacology*, **1994**, 47, 1957-63	6	21

322	Cytochrome P-450 forms and its inducibility by PCB isomers in black-headed gulls and black-tailed gulls. *Marine Pollution Bulletin*, **1992**, 24, 316-321	6.7	21
321	Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. *Xenobiotica*, **2015**, 45, 312-21	2	20
320	Monkey liver cytochrome P450 2C19 is involved in R- and S-warfarin 7-hydroxylation. *Biochemical Pharmacology*, **2012**, 84, 1691-5	6	20
319	Comparison of P450 Enzymes Between Cynomolgus Monkeys and Humans: P450 Identities, Protein Contents, Kinetic Parameters, and Potential for Inhibitory Profiles. *Current Drug Metabolism*, **2013**, 14, 239-252	3.5	20
318	Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants. *Drug Metabolism and Disposition*, **2011**, 39, 724-8	4	20
317	Genotoxic activation of benzophenone and its two metabolites by human cytochrome P450s in SOS/umu assay. *Mutation Research - Genetic Toxicology and Environmental Mutagenesis*, **2002**, 519, 199-204	2	20
316	Newly identified CYP2C93 is a functional enzyme in rhesus monkey, but not in cynomolgus monkey. *PLoS ONE*, **2011**, 6, e16923	3.7	20
315	Importance of cynomolgus monkeys in development of monoclonal antibody drugs. *Drug Metabolism and Pharmacokinetics*, **2019**, 34, 55-63	2.2	20
314	Marmoset Cytochrome P450 3A4 Ortholog Expressed in Liver and Small-Intestine Tissues Efficiently Metabolizes Midazolam, Alprazolam, Nifedipine, and Testosterone. *Drug Metabolism and Disposition*, **2017**, 45, 457-467	4	19
313	Human urine and plasma concentrations of bisphenol A extrapolated from pharmacokinetics established in in vivo experiments with chimeric mice with humanized liver and semi-physiological pharmacokinetic modeling. *Regulatory Toxicology and Pharmacology*, **2015**, 72, 71-6	3.4	19
312	Pharmacokinetics and effects on serum cholinesterase activities of organophosphorus pesticides acephate and chlorpyrifos in chimeric mice transplanted with human hepatocytes. *Regulatory Toxicology and Pharmacology*, **2014**, 70, 468-73	3.4	19
311	The human hepatic cell line HepaRG as a possible cell source for the generation of humanized liver TK-NOG mice. *Xenobiotica*, **2014**, 44, 146-53	2	19
310	Mutagenic activation of betel quid-specific N-nitrosamines catalyzed by human cytochrome P450 coexpressed with NADPH-cytochrome P450 reductase in Salmonella typhimurium YG7108. *Mutation Research - Genetic Toxicology and Environmental Mutagenesis*, **2005**, 581, 165-71	3	19
309	Roles of different cytochrome P450 enzymes in bioactivation of the potent hepatocarcinogen 3-methoxy-4-aminoazobenzene by rat and human liver microsomes. *Carcinogenesis*, **1991**, 12, 133-9	4.6	19
308	Comparison of p450 enzymes between cynomolgus monkeys and humans: p450 identities, protein contents, kinetic parameters, and potential for inhibitory profiles. *Current Drug Metabolism*, **2013**, 14, 239-52	3.5	19
307	Substrate Selectivities and Catalytic Activities of Marmoset Liver Cytochrome P450 2A6 Differed from Those of Human P450 2A6. *Drug Metabolism and Disposition*, **2015**, 43, 969-76	4	18
306	Physiologically Based Pharmacokinetic Models Predicting Renal and Hepatic Concentrations of Industrial Chemicals after Virtual Oral Doses in Rats. *Chemical Research in Toxicology*, **2020**, 33, 1736-1751	4	18
305	Evaluation of cytochrome P450 inductions by anti-epileptic drug oxcarbazepine, 10-hydroxyoxcarbazepine, and carbamazepine using human hepatocytes and HepaRG cells. *Xenobiotica*, **2016**, 46, 765-74	2	18

304	Cardiohemodynamic and electrophysiological effects of anti-influenza drug oseltamivir in vivo and in vitro. *Cardiovascular Toxicology*, **2013**, 13, 234-43	3.4	18
303	Hepatic microsomal UDP-glucuronosyltransferase (UGT) activities in the microminipig. *Biopharmaceutics and Drug Disposition*, **2014**, 35, 313-20	1.7	18
302	Metabolic activation of carcinogenic 1-nitropyrene by human cytochrome P450 1B1 in Salmonella typhimurium strain expressing an O-acetyltransferase in SOS/umu assay. *Mutation Research - Genetic Toxicology and Environmental Mutagenesis*, **2001**, 497, 223-33	3	18
301	Use of a newly developed tester strain Salmonella typhimurium NM2009 for the study of metabolic activation of carcinogenic aromatic amines by rat liver microsomal cytochrome P-450 enzymes. *Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology*, **1992**, 272, 183-92		18
300	Genetic polymorphism of cynomolgus and rhesus macaque CYP2C9. *Drug Metabolism and Pharmacokinetics*, **2015**, 30, 130-2	2.2	17
299	Potential for drug interactions mediated by polymorphic flavin-containing monooxygenase 3 in human livers. *Drug Metabolism and Pharmacokinetics*, **2015**, 30, 70-4	2.2	17
298	Human plasma concentrations of herbicidal carbamate molinate extrapolated from the pharmacokinetics established in in vivo experiments with chimeric mice with humanized liver and physiologically based pharmacokinetic modeling. *Regulatory Toxicology and Pharmacology*, **2014**, 70, 214-21	3.4	17
297	Polymorphisms of CYP2D17 in cynomolgus and rhesus macaques: an evidence of the genetic basis for the variability of CYP2D-dependent drug metabolism. *Drug Metabolism and Disposition*, **2014**, 42, 1407-10	4	17
296	Relationships between flavin-containing mono-oxygenase 3 (FMO3) genotype and trimethylaminuria phenotype in a Japanese population. *British Journal of Clinical Pharmacology*, **2014**, 77, 839-51	3.8	17
295	Eighteen novel polymorphisms of the CYP2A13 gene in Japanese. *Drug Metabolism and Pharmacokinetics*, **2003**, 18, 86-90	2.2	17
294	Determination and prediction of permeability across intestinal epithelial cell monolayer of a diverse range of industrial chemicals/drugs for estimation of oral absorption as a putative marker of hepatotoxicity. *Toxicology Reports*, **2020**, 7, 149-154	4.8	17
293	Human plasma concentrations of cytochrome P450 probes extrapolated from pharmacokinetics in cynomolgus monkeys using physiologically based pharmacokinetic modeling. *Xenobiotica*, **2015**, 45, 881-6	2	16
292	Physiologically based pharmacokinetic-pharmacodynamic modeling to predict concentrations and actions of sodium-dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubules. *Biopharmaceutics and Drug Disposition*, **2016**, 37, 491-506	1.7	16
291	Individual Differences in Metabolic Clearance of S-Warfarin Efficiently Mediated by Polymorphic Marmoset Cytochrome P450 2C19 in Livers. *Drug Metabolism and Disposition*, **2016**, 44, 911-5	4	16
290	Systematic identification and characterization of glutathione S-transferases in cynomolgus macaque. *Biochemical Pharmacology*, **2013**, 86, 679-90	6	16
289	Sex- and age-dependent gene expression in human liver: An implication for drug-metabolizing enzymes. *Drug Metabolism and Pharmacokinetics*, **2017**, 32, 100-107	2.2	16
288	Marmoset cytochrome P450 4A11, a novel arachidonic acid and lauric acid ω-hydroxylase expressed in liver and kidney tissues. *Xenobiotica*, **2017**, 47, 553-561	2	16
287	Variants in the flavin-containing monooxygenase 3 (FMO3) gene responsible for trimethylaminuria in a Japanese population. *Molecular Genetics and Metabolism*, **2012**, 107, 330-4	3.7	16

286	Mechanism-based inhibition of CYP1A1 and CYP3A4 by the furanocoumarin chalepensin. *Drug Metabolism and Pharmacokinetics*, **2013**, 28, 229-38	2.2	16
285	Characterization of microsomal glutathione S-transferases MGST1, MGST2, and MGST3 in cynomolgus macaque. *Drug Metabolism and Disposition*, **2013**, 41, 1621-5	4	16
284	Comparison of cytochrome P450 2C subfamily members in terms of drug oxidation rates and substrate inhibition. *Current Drug Metabolism*, **2012**, 13, 1145-59	3.5	16
283	Characterization of liver microsomal 7-ethoxycoumarin O-deethylation and chlorzoxazone 6-hydroxylation activities in Japanese and Caucasian subjects genotyped for CYP2E1 gene. *Archives of Toxicology*, **2000**, 74, 372-8	5.8	16
282	Fluorescence in situ hybridization analysis of chromosomal localization of three human cytochrome P450 2C genes (CYP2C8, 2C9, and 2C10) at 10q24.1. *Japanese Journal of Human Genetics*, **1994**, 39, 337-43		16
281	Roles of Human CYP2A6 and Monkey CYP2A24 and 2A26 Cytochrome P450 Enzymes in the Oxidation of 2,5,2Ç5ÖTetrachlorobiphenyl. *Drug Metabolism and Disposition*, **2016**, 44, 1899-1909	4	16
280	Evaluation of 89 compounds for identification of substrates for cynomolgus monkey CYP2C76, a new bupropion/nifedipine oxidase. *Drug Metabolism and Disposition*, **2015**, 43, 27-33	4	15
279	Oxidation of pyrene, 1-hydroxypyrene, 1-nitropyrene and 1-acetylpyrene by human cytochrome P450 2A13. *Xenobiotica*, **2016**, 46, 211-24	2	15
278	Metabolic profiles of pomalidomide in human plasma simulated with pharmacokinetic data in control and humanized-liver mice. *Xenobiotica*, **2017**, 47, 844-848	2	15
277	Discovery of genetic variants in CYP1D1: implication for functional integrity of CYP1D1 in cynomolgus macaques and rhesus macaques. *Drug Metabolism and Pharmacokinetics*, **2011**, 26, 627-31	2.2	15
276	Mechanism-based inhibition of cytochrome P450 (CYP)2A6 by chalepensin in recombinant systems, in human liver microsomes and in mice in vivo. *British Journal of Pharmacology*, **2011**, 163, 1250-62	8.6	15
275	Human Blood Concentrations of Dichlorodiphenyltrichloroethane (DDT) Extrapolated from Metabolism in Rats and Humans and Physiologically Based Pharmacokinetic Modeling. *Journal of Health Science*, **2010**, 56, 566-575		15
274	Three novel single nucleotide polymorphisms of the FMO3 gene in a Japanese population. *Drug Metabolism and Pharmacokinetics*, **2006**, 21, 245-7	2.2	15
273	Disparity in holoprotein/apoprotein ratios of different standards used for immunoquantification of hepatic cytochrome P450 enzymes. *Drug Metabolism and Disposition*, **2007**, 35, 1733-6	4	15
272	Structure-Function Studies of Naphthalene, Phenanthrene, Biphenyl, and Their Derivatives in Interaction with and Oxidation by Cytochromes P450 2A13 and 2A6. *Chemical Research in Toxicology*, **2016**, 29, 1029-40	4	15
271	Identification and analysis of CYP7A1, CYP17A1, CYP20A1, CYP27A1 and CYP51A1 in cynomolgus macaques. *Journal of Veterinary Medical Science*, **2014**, 76, 1647-50	1.1	14
270	Population pharmacokinetics of fluconazole after administration of fosfluconazole and fluconazole in critically ill patients. *Journal of Clinical Pharmacy and Therapeutics*, **2012**, 37, 356-63	2.2	14
269	Oxidation of Acenaphthene and Acenaphthylene by Human Cytochrome P450 Enzymes. *Chemical Research in Toxicology*, **2015**, 28, 268-78	4	14

268	CYP2C76 non-synonymous variants in cynomolgus and rhesus macaques. *Drug Metabolism and Pharmacokinetics*, **2012**, 27, 344-8	2.2	14
267	Genetic polymorphisms of glycine N-acyltransferase in Japanese individuals. *Drug Metabolism and Pharmacokinetics*, **2009**, 24, 114-7	2.2	14
266	Mild trimethylaminuria observed in a Japanese cohort with liver damage. *American Journal of Medicine*, **2005**, 118, 803-5	2.4	14
265	Effects of erythromycin and roxithromycin on oxidation of testosterone and nifedipine catalyzed by CYP3A4 in human liver microsomes. *Journal of Toxicological Sciences*, **1996**, 21, 215-26	1.9	14
264	Distribution, metabolism and excretion of N-nitrosobis(2-hydroxypropyl)amine in Wistar rats. *Carcinogenesis*, **1984**, 5, 1443-7	4.6	14
263	Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients. *Biochemical Pharmacology* , **2015**, 93, 104-9	6	13
262	Genetic polymorphisms of drug-metabolizing cytochrome P450 enzymes in cynomolgus and rhesus monkeys and common marmosets in preclinical studies for humans. *Biochemical Pharmacology*, **2018**, 153, 184-195	6	13
261	Human plasma concentrations of five cytochrome P450 probes extrapolated from pharmacokinetics in dogs and minipigs using physiologically based pharmacokinetic modeling. *Xenobiotica*, **2016**, 46, 759-64	2	13
260	Monkey liver cytochrome P450 2C9 is involved in caffeine 7-N-demethylation to form theophylline. *Xenobiotica*, **2013**, 43, 1037-42	2	13
259	Metabolism of P450 probe substrates by cynomolgus monkey CYP2C76. *Basic and Clinical Pharmacology and Toxicology*, **2011**, 109, 315-8	3.1	13
258	CYP2G2, pseudogenized in human, is expressed in nasal mucosa of cynomolgus monkey and encodes a functional drug-metabolizing enzyme. *Drug Metabolism and Disposition*, **2011**, 39, 717-23	4	13
257	Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. *Xenobiotica*, **2007**, 37, 717-24	2	13
256	Missense and nonsense mutations of the flavin-containing monooxygenase 3 gene in a Japanese cohort. *Drug Metabolism and Pharmacokinetics*, **2007**, 22, 61-4	2.2	13
255	Rat pulmonary microsomal cytochrome P-450 enzymes involved in the activation of procarcinogens. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **1992**, 284, 233-41	3.3	13
254	Strong Induction of Cytochrome P450 1A/3A, But not P450 2B, in Cultured Hepatocytes from Common Marmosets and Cynomolgus Monkeys by Typical Human P450 Inducing Agents. *Drug Metabolism Letters*, **2017**, 10, 244-253	2.1	13
253	Assessment of Protein Binding of 5-Hydroxythalidomide Bioactivated in Humanized Mice with Human P450 3A-Chromosome or Hepatocytes by Two-Dimensional Electrophoresis/Accelerator Mass Spectrometry. *Chemical Research in Toxicology*, **2016**, 29, 1279-81	4	13
252	Steady-State Human Pharmacokinetics of Monobutyl Phthalate Predicted by Physiologically Based Pharmacokinetic Modeling Using Single-Dose Data from Humanized-Liver Mice Orally Administered with Dibutyl Phthalate. *Chemical Research in Toxicology*, **2019**, 32, 333-340	4	13
251	Prediction of human pharmacokinetics of typical compounds by a physiologically based method using chimeric mice with humanized liver. *Xenobiotica*, **2019**, 49, 404-414	2	13

250	Comprehensive Evaluation for Substrate Selectivity of Cynomolgus Monkey Cytochrome P450 2C9, a New Efavirenz Oxidase. *Drug Metabolism and Disposition*, **2015**, 43, 1119-22	4	12
249	Collaborative Method Performance Study of the Measurement of Nicotine, Its Metabolites, and Total Nicotine Equivalents in Human Urine. *Cancer Epidemiology Biomarkers and Prevention*, **2018**, 27, 1083-1090	4	12
248	Effect of ketoconazole on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor teneligliptin: an open-label study in healthy white subjects in Germany. *Clinical Therapeutics*, **2014**, 36, 760-9	3.5	12
247	Drug interactions of diclofenac and its oxidative metabolite with human liver microsomal cytochrome P450 1A2-dependent drug oxidation. *Xenobiotica*, **2014**, 44, 10-6	2	12
246	Dose-dependent Effects of Cigarette Smoke on Blood Biomarkers in Healthy Japanese Volunteers: Observations from Smoking and Non-smoking. *Journal of Health Science*, **2009**, 55, 259-264		12
245	Activation of trans-1,2-dihydro-1,2-dihydroxy-6-aminochrysene to genotoxic metabolites by rat and human cytochromes P450. *Carcinogenesis*, **1994**, 15, 465-70	4.6	12
244	Oxidation of R- and S-omeprazole stereoselectively mediated by liver microsomal cytochrome P450 2C19 enzymes from cynomolgus monkeys and common marmosets. *Biochemical Pharmacology*, **2016**, 120, 56-62	6	12
243	Cytochrome P450 2A6 and other human P450 enzymes in the oxidation of flavone and flavanone. *Xenobiotica*, **2019**, 49, 131-142	2	12
242	Chimeric mice with humanized liver as a model for testing organophosphate and carbamate pesticide exposure. *Pest Management Science*, **2018**, 74, 1424-1430	4.6	11
241	Immunochemical detection of cytochrome P450 enzymes in small intestine microsomes of male and female untreated juvenile cynomolgus monkeys. *Xenobiotica*, **2014**, 44, 769-74	2	11
240	Expression profile of hepatic genes in cynomolgus macaques bred in Cambodia, China, and Indonesia: implications for cytochrome P450 genes. *Drug Metabolism and Pharmacokinetics*, **2012**, 27, 307-16	2.2	11
239	Complex mechanism underlying transcriptional control of the haplotyped flavin-containing monooxygenase 3 (FMO3) gene in Japanese: different regulation between mutations in 5'-upstream distal region and common element in proximal region. *Drug Metabolism and Pharmacokinetics*, **2008**, 23, 54-8	2.2	11
238	A New Marmoset P450 4F12 Enzyme Expressed in Small Intestines and Livers Efficiently Metabolizes Antihistaminic Drug Ebastine. *Drug Metabolism and Disposition*, **2016**, 44, 833-41	4	11
237	Marmoset cytochrome P450 2J2 mainly expressed in small intestines and livers effectively metabolizes human P450 2J2 probe substrates, astemizole and terfenadine. *Xenobiotica*, **2016**, 46, 977-85	2	11
236	Regio- and Stereo-Selective Oxidation of a Cardiovascular Drug, Metoprolol, Mediated by Cytochrome P450 2D and 3A Enzymes in Marmoset Livers. *Drug Metabolism and Disposition*, **2017**, 45, 896-899	4	10
235	Functional and molecular characterization of UDP-glucuronosyltransferase 2 family in cynomolgus macaques. *Biochemical Pharmacology*, **2019**, 163, 335-344	6	10
234	Zone analysis by two-dimensional electrophoresis with accelerator mass spectrometry of in vivo protein bindings of idiosyncratic hepatotoxicants troglitazone and flutamide bioactivated in chimeric mice with humanized liver. *Toxicology Research*, **2015**, 4, 106-111	2.6	10
233	In vivo and in vitro diclofenac 5-hydroxylation mediated primarily by cytochrome P450 3A enzymes in common marmoset livers genotyped for P450 2C19 variants. *Biochemical Pharmacology*, **2018**, 152, 272-278	6	10

232	Oxidation of 1-chloropyrene by human CYP1 family and CYP2A subfamily cytochrome P450 enzymes: catalytic roles of two CYP1B1 and five CYP2A13 allelic variants. *Xenobiotica*, **2018**, 48, 565-575	2	10
231	Molecular Cloning, Tissue Distribution, and Functional Characterization of Marmoset Cytochrome P450 1A1, 1A2, and 1B1. *Drug Metabolism and Disposition*, **2016**, 44, 8-15	4	10
230	CYP2D44 polymorphisms in cynomolgus and rhesus macaques. *Molecular Biology Reports*, **2015**, 42, 1149-55	2.5	10
229	Comparison of catalytic properties of cytochromes P450 3A4 and 3A5 by molecular docking simulation. *Drug Metabolism Letters*, **2014**, 8, 43-50	2.1	10
228	Cloning, expression, and characterization of CYP3A43 cDNA in cynomolgus macaque (Macaca fascicularis). *Drug Metabolism Letters*, **2009**, 3, 228-33	2.1	10
227	Identification and characterization of CYP2B6 cDNA in cynomolgus macaques (Macaca fascicularis). *Journal of Veterinary Medical Science*, **2009**, 71, 1653-6	1.1	10
226	Pharmacokinetic investigation of increased efficacy against malignant gliomas of carboplatin combined with hyperbaric oxygenation. *Neurologia Medico-Chirurgica*, **2009**, 49, 193-7; discussion 197	2.6	10
225	Effects of propofol analogs on glucuronidation of propofol, an anesthetic drug, by human liver microsomes. *Drug Metabolism Letters*, **2007**, 1, 77-9	2.1	10
224	Linkage between the distribution of mutations in the CYP2C18 and CYP2C19 genes in the Japanese and Caucasian. *Xenobiotica*, **1998**, 28, 403-11	2	10
223	Metabolic deactivation of furylfuramide by cytochrome P450 in human and rat liver microsomes. *Carcinogenesis*, **1990**, 11, 103-10	4.6	10
222	Metabolism of desloratadine by chimeric TK-NOG mice transplanted with human hepatocytes. *Xenobiotica*, **2020**, 50, 733-740	2	10
221	Individual differences in in vitro and in vivo metabolic clearances of the antipsychotic drug olanzapine from non-smoking and smoking Japanese subjects genotyped for cytochrome P4502D6 and flavincontaining monooxygenase 3. *Human Psychopharmacology*, **2016**, 31, 83-92	2.3	10
220	Pre-incubation with cyclosporine A potentiates its inhibitory effects on pitavastatin uptake mediated by recombinantly expressed cynomolgus monkey hepatic organic anion transporting polypeptide. *Biopharmaceutics and Drug Disposition*, **2016**, 37, 479-490	1.7	10
219	Prediction of Human Distribution Volumes of Compounds in Various Elimination Phases Using Physiologically Based Pharmacokinetic Modeling and Experimental Pharmacokinetics in Animals. *Drug Metabolism and Disposition*, **2019**, 47, 114-123	4	10
218	Characterization of microminipigs as an in vivo experimental model for cardiac safety pharmacology. *Journal of Pharmacological Sciences*, **2017**, 133, 103-109	3.7	9
217	Inhibitory effects of antihypertensive drugs on human cytochrome P450 2J2 activity: Potent inhibition by azelnidipine and manidipine. *Chemico-Biological Interactions*, **2019**, 306, 1-9	5	9
216	Immunochemical quantification of cynomolgus CYP2J2, CYP4A and CYP4F enzymes in liver and small intestine. *Xenobiotica*, **2015**, 45, 124-30	2	9
215	Human Aldehyde Oxidase 1-Mediated Carbazeran Oxidation in Chimeric TK-NOG Mice Transplanted with Human Hepatocytes. *Drug Metabolism and Disposition*, **2020**, 48, 580-586	4	9

214	Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19. *Xenobiotica*, **2018**, 48, 720-726	2	9
213	In vivo individual variations in pharmacokinetics of efavirenz in cynomolgus monkeys genotyped for cytochrome P450 2C9. *Biopharmaceutics and Drug Disposition*, **2016**, 37, 379-83	1.7	9
212	Molecular and functional characterization of UDP-glucuronosyltransferase 1A in cynomolgus macaques. *Biochemical Pharmacology*, **2018**, 155, 172-181	6	9
211	Site-specific oxidation of flavanone and flavone by cytochrome P450 2A6 in human liver microsomes. *Xenobiotica*, **2019**, 49, 791-802	2	9
210	Expression and inducibility of cytochrome P450s in human hepatocytes isolated from chimeric mice with humanised livers. *Xenobiotica*, **2019**, 49, 678-687	2	9
209	Human HepaRG Cells can be Cultured in Hanging-drop Plates for Cytochrome P450 Induction and Function Assays. *Drug Metabolism Letters*, **2015**, 9, 3-7	2.1	9
208	A rapid multiplex PCR assay that can reliably discriminate the cytochrome P450 2D6 whole-gene deletion allele from 2D6*10 alleles. *Clinica Chimica Acta*, **2012**, 413, 1675-7	6.2	9
207	Clinical evidence of pharmacokinetic changes in thalidomide therapy. *Drug Metabolism and Pharmacokinetics*, **2013**, 28, 38-43	2.2	9
206	Direct genotyping of Cytochrome P450 2A6 whole gene deletion from human blood samples by the SmartAmp method. *Clinica Chimica Acta*, **2011**, 412, 1249-51	6.2	9
205	Identification and characterization of CYP2C18 in the cynomolgus macaque (Macaca fascicularis). *Journal of Veterinary Medical Science*, **2010**, 72, 225-8	1.1	9
204	Comparison of the Contributions of Cytochromes P450 3A4 and 3A5 in Drug Oxidation Rates and Substrate Inhibition. *Journal of Health Science*, **2010**, 56, 239-256		9
203	Species differences in hydrolase activities toward OT-7100 responsible for different bioavailability in rats, dogs, monkeys and humans. *Xenobiotica*, **2006**, 36, 301-14	2	9
202	Cytochrome P450 reconstitution systems. *Methods in Molecular Biology*, **2006**, 320, 61-71	1.4	9
201	Cytochrome P450 reconstitution systems. *Methods in Molecular Biology*, **1998**, 107, 85-93	1.4	9
200	Activation of carcinogenic N-nitrosopropylamines to mutagens by lung and pancreas S9 fractions from various animal species and man. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **1986**, 160, 159-69	3.3	9
199	Molecular and Functional Characterization of N-Acetyltransferases NAT1 and NAT2 in Cynomolgus Macaque. *Chemical Research in Toxicology*, **2018**, 31, 1269-1276	4	9
198	Activation of toxic chemicals by cytochrome P450 enzymes: regio- and stereoselective oxidation of aflatoxin B1. *Advances in Experimental Medicine and Biology*, **1996**, 387, 7-15	3.6	9
197	Intravenous Administration of Apomorphine Does NOT Induce Long QT Syndrome: Experimental Evidence from In Vivo Canine Models. *Basic and Clinical Pharmacology and Toxicology*, **2015**, 116, 468-75	3.1	8

196	Human plasma metabolic profiles of benzydamine, a flavin-containing monooxygenase probe substrate, simulated with pharmacokinetic data from control and humanized-liver mice. *Xenobiotica* , **2018**, 48, 117-123	2	8
195	Improved Intranasal Retentivity and Transnasal Absorption Enhancement by PEGylated Poly-l-ornithine. *Pharmaceuticals*, **2018**, 11,	5.2	8
194	Human plasma and liver concentrations of styrene estimated by combining a simple physiologically based pharmacokinetic model with rodent data. *Journal of Toxicological Sciences*, **2019**, 44, 543-548	1.9	8
193	Species Difference between Cynomolgus Monkeys and Humans on Cytochromes P450 2D and 3A-Dependent Drug Oxidation Activities in Liver Microsomes. *Journal of Health Science*, **2011**, 57, 164-170		8
192	Cynomolgus macaque CYP4 isoforms are functional, metabolizing arachidonic acid. *Journal of Veterinary Medical Science*, **2011**, 73, 487-90	1.1	8
191	Human cytochrome P450 1A1 is a novel target gene of liver X receptor *Drug Metabolism and Pharmacokinetics*, **2011**, 26, 451-7	2.2	8
190	Bonitos with low content of malodorous trimethylamine as palliative care for self-reported Japanese trimethylaminuria subjects. *Drug Metabolism and Pharmacokinetics*, **2009**, 24, 549-52	2.2	8
189	Effects of histidine-tag on recombinant human cytochrome P450 3A5 catalytic activity in reconstitution systems. *Drug Metabolism Letters*, **2009**, 3, 207-11	2.1	8
188	Effects of enzyme sources on midazolam 1-hydroxylation activity catalyzed by recombinant cytochrome P450 3A4 in combination with NADPH-cytochrome P450 reductase. *Drug Metabolism Letters*, **2008**, 2, 190-2	2.1	8
187	Molecular characterization of functional UDP-glucuronosyltransferases 1A and 2B in common marmosets. *Biochemical Pharmacology*, **2020**, 172, 113748	6	8
186	Development of a genotyping tool for a functionally relevant CYP2C19 allele (Phe100Asn, Ala103Val and Ile112Leu) in cynomolgus macaques. *Journal of Veterinary Medical Science*, **2016**, 78, 147-8	1.1	8
185	Pharmacokinetics and metabolism of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator, in rats and monkeys. *Biopharmaceutics and Drug Disposition*, **2019**, 40, 12-17	1.7	8
184	R-warfarin clearances from plasma associated with polymorphic cytochrome P450 2C19 and simulated by individual physiologically based pharmacokinetic models for 11 cynomolgus monkeys. *Xenobiotica*, **2018**, 48, 206-210	2	8
183	Molecular Cloning and Characterization of Marmoset Aldehyde Oxidase. *Drug Metabolism and Disposition*, **2017**, 45, 883-886	4	7
182	Functional characterization for polymorphic organic anion transporting polypeptides (OATP/SLCO1B1, 1B3, 2B1) of monkeys recombinantly expressed with various OATP probes. *Biopharmaceutics and Drug Disposition*, **2019**, 40, 62-69	1.7	7
181	Oxidation of Flavone, 5-Hydroxyflavone, and 5,7-Dihydroxyflavone to Mono-, Di-, and Tri-Hydroxyflavones by Human Cytochrome P450 Enzymes. *Chemical Research in Toxicology*, **2019**, 32, 1268-1280	4	7
180	Systematic characterization of glutathione S-transferases in common marmosets. *Biochemical Pharmacology*, **2020**, 174, 113835	6	7
179	Induction of human cytochrome P450 3A enzymes in cultured placental cells by thalidomide and relevance to bioactivation and toxicity. *Journal of Toxicological Sciences*, **2017**, 42, 343-348	1.9	7

178	Association with polymorphic marmoset cytochrome P450 2C19 of in vivo hepatic clearances of chirally separated R-omeprazole and S-warfarin using individual marmoset physiologically based pharmacokinetic models. *Xenobiotica*, **2018**, 48, 1072-1077	2	7
177	Association of pharmacokinetic profiles of lenalidomide in human plasma simulated using pharmacokinetic data in humanized-liver mice with liver toxicity detected by human serum albumin RNA. *Journal of Toxicological Sciences*, **2018**, 43, 369-375	1.9	7
176	Suitable albumin concentrations for enhanced drug oxidation activities mediated by human liver microsomal cytochrome P450 2C9 and other forms predicted with unbound fractions and partition/distribution coefficients of model substrates. *Xenobiotica*, **2019**, 49, 557-562	2	7
175	Genetic variants of flavin-containing monooxygenase 3 (FMO3) derived from Japanese subjects with the trimethylaminuria phenotype and whole-genome sequence data from a large Japanese database. *Drug Metabolism and Pharmacokinetics*, **2019**, 34, 334-339	2.2	7
174	Comparison of Steroid Hormone Hydroxylations by and Docking to Human Cytochromes P450 3A4 and 3A5. *Journal of Pharmacy and Pharmaceutical Sciences*, **2019**, 22, 332-339	3.4	7
173	Trimethylamine generation in patients receiving hemodialysis treated with l-carnitine. *CKJ: Clinical Kidney Journal*, **2014**, 7, 329	4.5	7
172	Fluvoxamine by itself has potential to directly induce long QT syndrome at supra-therapeutic concentrations. *Journal of Toxicological Sciences*, **2015**, 40, 33-42	1.9	7
171	Similar substrate specificity of cynomolgus monkey cytochrome P450 2C19 to reported human P450 2C counterpart enzymes by evaluation of 89 drug clearances. *Biopharmaceutics and Drug Disposition*, **2015**, 36, 636-43	1.7	7
170	Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling. *Biopharmaceutics and Drug Disposition*, **2015**, 36, 148-62	1.7	7
169	Genotyping of wild-type cytochrome P450 2A6 and whole-gene deletion using human blood samples and a multiplex real-time polymerase chain reaction method with dual-labeled probes. *Clinica Chimica Acta*, **2015**, 441, 71-4	6.2	7
168	Intravenous and oral administrations of DD2 [7-Amino-2-(sulfanylmethyl)heptanoic acid] produce thrombolysis through inhibition of plasma TAFIa in rats with tissue factor-induced microthrombosis. *Thrombosis Research*, **2012**, 130, e222-8	8.2	7
167	A newly developed DNA microarray is useful to assess induction of cytochromes p450 in the cynomolgus monkey. *Drug Metabolism and Pharmacokinetics*, **2011**, 26, 228-35	2.2	7
166	Blood Concentrations of 1,4-Dioxane in Humans after Oral Administration Extrapolated from In Vivo Rat Pharmacokinetics, In Vitro Human Metabolism, and Physiologically Based Pharmacokinetic Modeling. *Journal of Health Science*, **2010**, 56, 557-565		7
165	Identification of catalase in human livers as a factor that enhances phenytoin dihydroxy metabolite formation by human liver microsomes. *Biochemical Pharmacology*, **2002**, 63, 2081-90	6	7
164	The marmoset cytochrome P450 superfamily: Sequence/phylogenetic analyses, genomic structure, and catalytic function. *Biochemical Pharmacology*, **2020**, 171, 113721	6	7
163	Prediction of Input Parameters for Simplified Physiologically Based Pharmacokinetic Models for Estimating Plasma, Liver, and Kidney Exposures in Rats after Oral Doses of 246 Disparate Chemicals. *Chemical Research in Toxicology*, **2021**, 34, 507-513	4	7
162	Cytochrome P450 1A1, 2C9, 2C19, and 3A4 Polymorphisms Account for Interindividual Variability of Toxicological Drug Metabolism in Cynomolgus Macaques. *Chemical Research in Toxicology*, **2018**, 31, 1373-1381	4	7
161	Ratio of serum levels of AGEs to soluble RAGE is correlated with trimethylamine-N-oxide in non-diabetic subjects. *International Journal of Food Sciences and Nutrition*, **2017**, 68, 1013-1020	3.7	6

160	Survey of Drug Oxidation Activities in Hepatic and Intestinal Microsomes of Individual Common Marmosets, a New Nonhuman Primate Animal Model. *Current Drug Metabolism*, **2019**, 20, 103-113	3.5	6
159	Molecular and functional characterization of cytosolic sulfotransferases in cynomolgus macaque. *Biochemical Pharmacology*, **2019**, 166, 153-162	6	6
158	Marmoset pulmonary cytochrome P450 2F1 oxidizes biphenyl and 7-ethoxycoumarin and hepatic human P450 substrates. *Xenobiotica*, **2018**, 48, 656-662	2	6
157	Caffeine 7-N-demethylation and C-8-oxidation mediated by liver microsomal cytochrome P450 enzymes in common marmosets. *Xenobiotica*, **2016**, 46, 573-578	2	6
156	Cytochrome P450-dependent drug oxidation activities in commercially available hepatocytes derived from human induced pluripotent stem cells cultured for 3 weeks. *Journal of Toxicological Sciences*, **2018**, 43, 241-245	1.9	6
155	Human urinary concentrations of monoisononyl phthalate estimated using physiologically based pharmacokinetic modeling and experimental pharmacokinetics in humanized-liver mice orally administered with diisononyl phthalate. *Xenobiotica*, **2019**, 49, 513-520	2	6
154	Analysis of six novel flavin-containing monooxygenase 3 () gene variants found in a Japanese population suffering from trimethylaminuria. *Molecular Genetics and Metabolism Reports*, **2015**, 5, 89-93	1.8	6
153	Different metabolites of human hepatotoxic pyrazolopyrimidine derivative 5-n-butyl-pyrazolo[1,5-a]pyrimidine produced by human, rat and monkey cytochrome P450 1A2 and liver microsomes. *Basic and Clinical Pharmacology and Toxicology*, **2012**, 110, 405-8	3.1	6
152	Stable and episodic/bolus patterns of methylmercury exposure on mercury accumulation and histopathologic alterations in the nervous system. *Environmental Research*, **2017**, 152, 446-453	7.9	6
151	Expression of cytochromes p450 in fetal, infant, and juvenile liver of cynomolgus macaques. *Drug Metabolism and Pharmacokinetics*, **2011**, 26, 621-6	2.2	6
150	Human liver enzymes responsible for metabolic elimination of tyramine; a vasopressor agent from daily food. *Drug Metabolism Letters*, **2011**, 5, 216-9	2.1	6
149	Human papillomavirus,Chlamydia trachomatis, and other risk factors associated with cervical cancer in China. *International Journal of Clinical Oncology*, **1998**, 3, 81-87	4.2	6
148	Increased distribution of carboplatin, an anti-cancer agent, to rat brains with the aid of hyperbaric oxygenation. *Xenobiotica*, **2008**, 38, 1471-5	2	6
147	Sexual behaviour and high risk human papillomavirus infections in Japanese women. *Sexually Transmitted Infections*, **2005**, 81, 280-2	2.8	6
146	Metabolic profiles of coumarin in human plasma extrapolated from a rat data set with a simplified physiologically based pharmacokinetic model. *Journal of Toxicological Sciences*, **2020**, 45, 695-700	1.9	6
145	Human Plasma Concentrations of Tolbutamide and Acetaminophen Extrapolated from in vivo Animal Pharmacokinetics Using in vitro Human Hepatic Clearances and Simple Physiologically Based Pharmacokinetic Modeling for Radio-labeled Microdose Clinical Studies. *Radioisotopes*, **2015**,	0.1	6
144	Different Effects of <i>TERT</i>, <i>TP</i>63, and <i>CYP</i>2<i>A</i>6 Polymorphism on Individual Risk of Tobacco-Related Lung Cancer in Male Japanese Smokers. *Journal of Cancer Therapy*, **2011**, 02, 690-696	0.2	6
143	An improved TK-NOG mouse as a novel platform for humanized liver that overcomes limitations in both male and female animals. *Drug Metabolism and Pharmacokinetics*, **2021**, 42, 100410	2.2	6

142	Functionally relevant genetic variants of glutathione S-transferase GSTM5 in cynomolgus and rhesus macaques. *Xenobiotica*, **2019**, 49, 995-1000	2	6
141	Novel variants and haplotypes of human gene associated with Japanese subjects suffering from trimethylaminuria. *Xenobiotica*, **2019**, 49, 1244-1250	2	6
140	Methyl-hydroxylation and subsequent oxidation to produce carboxylic acid is the major metabolic pathway of tolbutamide in chimeric TK-NOG mice transplanted with human hepatocytes. *Xenobiotica*, **2021**, 51, 582-589	2	6
139	In vivo Analysis of the Anti-atrial Fibrillatory, Proarrhythmic and Cardiodepressive Profiles of Dronedarone as a Guide for Safety Pharmacological Evaluation of Antiarrhythmic Drugs. *Cardiovascular Toxicology*, **2018**, 18, 242-251	3.4	6
138	Genetic Variants of Glutathione S-Transferase GSTT1 and GSTT2 in Cynomolgus Macaques: Identification of GSTT Substrates and Functionally Relevant Alleles. *Chemical Research in Toxicology* , **2018**, 31, 1086-1091	4	6
137	Functional characterization and tissue expression of marmoset cytochrome P450 2E1. *Biopharmaceutics and Drug Disposition*, **2017**, 38, 394-397	1.7	5
136	Efavirenz clearances in vitro and in vivo in six cynomolgus monkeys associated with polymorphic cytochrome P450 2C9 and simulated by individual physiologically based pharmacokinetic models. *Biopharmaceutics and Drug Disposition*, **2017**, 38, 439-442	1.7	5
135	Point mutation of cytochrome P450 2A6 (a polymorphic variant CYP2A6.25) confers new substrate specificity towards flavonoids. *Biopharmaceutics and Drug Disposition*, **2015**, 36, 552-63	1.7	5
134	Different Hepatic Concentrations of Bromobenzene, 1,2-Dibromobenzene, and 1,4-Dibromobenzene in Humanized-Liver Mice Predicted Using Simplified Physiologically Based Pharmacokinetic Models as Putative Markers of Toxicological Potential. *Chemical Research in Toxicology*, **2020**, 33, 3048-3053	4	5
133	Preference for -demethylation reactions in the oxidation of 2, 3, and 4methoxyflavones by human cytochrome P450 enzymes. *Xenobiotica*, **2020**, 50, 1158-1169	2	5
132	Human plasma and urinary metabolic profiles of trimethylamine and trimethylamine N-oxide extrapolated using a simple physiologically based pharmacokinetic model. *Journal of Toxicological Sciences*, **2017**, 42, 485-490	1.9	5
131	Upholding science in health, safety and environmental risk assessments and regulations. *Toxicology* , **2016**, 371, 12-16	4.4	5
130	Individual differences in in vitro and in vivo metabolic clearances of antipsychotic risperidone from Japanese subjects genotyped for cytochrome P450 2D6 and 3A5. *Human Psychopharmacology*, **2016**, 31, 93-102	2.3	5
129	Adult and infant pharmacokinetic profiling of dihydrocodeine using physiologically based pharmacokinetic modeling. *Biopharmaceutics and Drug Disposition*, **2019**, 40, 350-357	1.7	5
128	Differences in Toxicological and Pharmacological Responses Mediated by Polymorphic Cytochromes P450 and Related Drug-Metabolizing Enzymes. *Chemical Research in Toxicology*, **2017**, 30, 53-60	4	5
127	Dataset for genotyping validation of cytochrome P450 2A6 whole-gene deletion (CYP2A6*4) by real-time polymerase chain reaction platforms. *Data in Brief*, **2015**, 5, 642-5	1.2	5
126	Drug Metabolism and Toxicity in Chimeric Mice with Humanized Liver. *Journal of Health Science*, **2011**, 57, 22-27		5
125	Activities of cytochrome p450 enzymes in liver and kidney microsomes from systemic carnitine deficiency mice with a gene mutation of carnitine/organic cation transporter. *Drug Metabolism and Pharmacokinetics*, **2002**, 17, 47-53	2.2	5

124	Influence of microsomal and cytosolic fractions from the liver of 4 animal species and man on the mutagenicity of carcinogenic aminoazo dyes and nature of the mutagenicity-enhancing factor in the cytosol from rat liver. *Chemical and Pharmaceutical Bulletin*, **1984**, 32, 3641-50	1.9	5
123	Effects of ADH1C, ALDH2, and CYP2A6 Polymorphisms on Individual Risk of Tobacco-Related Lung Cancer in Male Japanese Smokers. *Journal of Cancer Therapy*, **2013**, 04, 29-35	0.2	5
122	Pharmacokinetics of anticoagulant edoxaban in overdose in a Japanese patient transported to hospital. *Journal of Pharmaceutical Health Care and Sciences*, **2020**, 6, 20	1.8	5
121	Non-synonymous genetic variants of flavin-containing monooxygenase 3 (FMO3) in cynomolgus macaques. *Drug Metabolism and Pharmacokinetics*, **2019**, 34, 104-107	2.2	5
120	Regioselective hydroxylation of an antiarrhythmic drug, propafenone, mediated by rat liver cytochrome P450 2D2 differs from that catalyzed by human P450 2D6. *Xenobiotica*, **2019**, 49, 1323-1331	2	5
119	Marmoset cytochrome P450 2B6, a propofol hydroxylase expressed in liver. *Xenobiotica*, **2019**, 49, 265-269	2	5
118	Metabolic Profiles of Tetrabromobisphenol A in Humans Extrapolated from Humanized-Liver Mouse Data Using a Simplified Physiologically Based Pharmacokinetic Model. *Chemical Research in Toxicology*, **2021**, 34, 522-528	4	5
117	Assessment of multiple cytochrome P450 activities in metabolically inactivated human liver microsomes and roles of P450 2C isoforms in reaction phenotyping studies. *Biopharmaceutics and Drug Disposition*, **2018**, 39, 116-121	1.7	5
116	Progesterone hydroxylation by cytochromes P450 2C and 3A enzymes in marmoset liver microsomes. *Xenobiotica*, **2018**, 48, 757-763	2	5
115	Aryl hydrocarbon hydroxylase represents CYP1B1, and not CYP1A1, in human freshly isolated white cells: trimodal distribution of Japanese population according to induction of CYP1B1 mRNA by environmental dioxins. *Cancer Epidemiology Biomarkers and Prevention*, **2003**, 12, 219-22	4	5
114	Marmoset Flavin-Containing Monooxygenase 3 in the Liver Is a Major Benzydamine and Sulindac Sulfide Oxygenase. *Drug Metabolism and Disposition*, **2017**, 45, 497-500	4	4
113	Genetic variants of N-acetyltransferases 1 and 2 (NAT1 and NAT2) in cynomolgus and rhesus macaques. *Biochemical Pharmacology*, **2020**, 177, 113996	6	4
112	Terfenadine t-butyl hydroxylation catalyzed by human and marmoset cytochrome P450 3A and 4F enzymes in livers and small intestines. *Xenobiotica*, **2018**, 48, 342-347	2	4
111	Systematic approach to optimize a pretreatment method for ultrasensitive liquid chromatography with tandem mass spectrometry analysis of multiple target compounds in biological samples. *Journal of Separation Science*, **2016**, 39, 3212-20	3.4	4
110	A Case of Delayed Emergence After Propofol Anesthesia: Genetic Analysis. *A & A Case Reports*, **2016**, 7, 243-246		4
109	Analysis of gene expression for microminipig liver transcriptomes using parallel long-read technology and short-read sequencing. *Biopharmaceutics and Drug Disposition*, **2016**, 37, 220-32	1.7	4
108	Human plasma concentrations of trimethylamine N-oxide extrapolated using pharmacokinetic modeling based on metabolic profiles of deuterium-labeled trimethylamine in humanized-liver mice. *Journal of Toxicological Sciences*, **2018**, 43, 387-393	1.9	4
107	CYP1B1 is polymorphic in cynomolgus and rhesus macaques. *Journal of Veterinary Medical Science*, **2011**, 73, 1229-31	1.1	4

106	Genetic polymorphism of bile acid CoA: amino acid N-acyltransferase in Japanese individuals. *Drug Metabolism and Pharmacokinetics*, **2007**, 22, 125-8	2.2	4
105	Activities of rat cytochrome P450 3A and 2C isoforms are increased in vivo by magnesium sulfate as evidenced by enhanced oxidation of bupivacaine and testosterone in liver microsomes. *Drug Metabolism and Pharmacokinetics*, **2006**, 21, 201-7	2.2	4
104	High-performance liquid chromatographic assay for carboplatin in ultrafiltered plasma combined with hyperbaric oxygenation. *Drug Metabolism and Pharmacokinetics*, **2006**, 21, 429-31	2.2	4
103	A major genotype in UDP-glucuronosyltransferase 2B15. *Drug Metabolism and Pharmacokinetics*, **2002**, 17, 164-6	2.2	4
102	Mutagenicity of N-nitrosodiethanolamine in the Salmonella/microsome test. *Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis*, **1987**, 192, 91-4		4
101	Cytochrome P450 2A6 Phenotyping Using Dietary Caffeine Salivary Metabolite Ratios and Genotyping Using Blood on Storage Cards in Non-smoking Japanese Volunteers. *Drug Metabolism Letters*, **2017**, 10, 240-243	2.1	4
100	Prediction of circulating human metabolites of pemafibrate, a novel antidyslipidemic drug, using chimeric mice with humanized liver. *Xenobiotica*, **2020**, 50, 769-775	2	4
99	Predicted Contributions of Flavin-containing Monooxygenases to the N-oxygenation of Drug Candidates Based on their Estimated Base Dissociation Constants. *Current Drug Metabolism*, **2021**, 22, 208-214	3.5	4
98	Simple pharmacokinetic models accounting for drug monitoring results of atomoxetine and its 4-hydroxylated metabolites in Japanese pediatric patients genotyped for cytochrome P450 2D6. *Drug Metabolism and Pharmacokinetics*, **2020**, 35, 191-200	2.2	4
97	Predicting successful/unsuccessful extrapolation for in vivo total clearance of model compounds with a variety of hepatic intrinsic metabolism and protein bindings in humans from pharmacokinetic data using chimeric mice with humanised liver. *Xenobiotica*, **2020**, 50, 526-535	2	4
96	Metabolic activation and deactivation of dietary-derived coumarin mediated by cytochrome P450 enzymes in rat and human liver preparations. *Journal of Toxicological Sciences*, **2021**, 46, 371-378	1.9	4
95	Pharmacokinetics of primary oxidative metabolites of thalidomide in rats and in chimeric mice humanized with different human hepatocytes. *Journal of Toxicological Sciences*, **2021**, 46, 311-317	1.9	4
94	Pharmacokinetic modeling of over-the-counter drug diphenhydramine self-administered in overdoses in Japanese patients admitted to hospital. *Journal of Pharmaceutical Health Care and Sciences*, **2021**, 7, 32	1.8	4
93	Predicted values for human total clearance of a variety of typical compounds with differently humanized-liver mouse plasma data. *Drug Metabolism and Pharmacokinetics*, **2020**, 35, 389-396	2.2	3
92	Increased plasma concentrations of an antidyslipidemic drug pemafibrate co-administered with rifampicin or cyclosporine A in cynomolgus monkeys genotyped for the organic anion transporting polypeptide 1B1. *Drug Metabolism and Pharmacokinetics*, **2020**, 35, 354-360	2.2	3
91	Expression of cytochrome P450 regulators in cynomolgus macaque. *Xenobiotica*, **2018**, 48, 695-703	2	3
90	In vitro inhibition and enhancement of liver microsomal S-777469 metabolism by long-chain fatty acids and serum albumin: insight into in vitro and in vivo discrepancy of metabolite formation in humans. *Xenobiotica*, **2016**, 46, 495-502	2	3
89	In vivo hepatic clearance of lipophilic drugs predicted by in vitro uptake data into cryopreserved hepatocytes suspended in sera of rats, guinea pigs, monkeys and humans. *Xenobiotica*, **2019**, 49, 887-894	2	3

88	Cloning and expression of a novel catechol-O-methyltransferase in common marmosets. *Journal of Veterinary Medical Science*, **2017**, 79, 267-272	1.1	3
87	Increased transendothelial permeability of anti-cancer agent carboplatin with the aid of hyperbaric oxygenation. *Xenobiotica*, **2008**, 38, 1298-304	2	3
86	Novel mutations of the CYP2A6 gene in a Thai population with lowered capacity of coumarin 7-hydroxylation. *Drug Metabolism and Pharmacokinetics*, **2002**, 17, 161-3	2.2	3
85	Metabolic Activation of Chrysene by Human Hepatic and Pulmonary Cytochrome P450 Enzymes. *Polycyclic Aromatic Compounds*, **1996**, 10, 59-66	1.3	3
84	Plasma, liver, and kidney exposures in rats after oral doses of industrial chemicals predicted using physiologically based pharmacokinetic models: A case study of perfluorooctane sulfonic acid. *Journal of Toxicological Sciences*, **2020**, 45, 763-767	1.9	3
83	Genotoxic Activation of the Environmental Pollutant 3-Nitrobenzanthrone by Human Cytochrome P450 Enzymes Expressed in Salmonella typhimurium umu Tester Strains. *Genes and Environment*, **2007**, 29, 146-152	2.8	3
82	Effect of Genetic Polymorphism of CYP2A6 on Individual Susceptibility to Colorectal Tumors in Japanese Smokers. *Journal of Cancer Therapy*, **2012**, 03, 207-215	0.2	3
81	HYPERCALCEMIA IN PATIENTS WITH ORAL CANCER. *Japanese Jornal of Head and Neck Cancer*, **2000**, 26, 95-100		3
80	Carcinoma of tongue in a patient with Fanconi's anemia.. *Nihon Koku Geka Gakkai Zasshi*, **2001**, 47, 567-570	0.1	3
79	Different Roles of Human Cytochrome P450 2C9 and 3A Enzymes in Diclofenac 4'and 5-Hydroxylations Mediated by Metabolically Inactivated Human Hepatocytes in Previously Transplanted Chimeric Mice. *Chemical Research in Toxicology*, **2020**, 33, 634-639	4	3
78	Expression of functional sulfotransferases (SULT) 1A1, 1A3, 1B1, 1C2, 1E1, and 2A1 in common marmosets. *Biochemical Pharmacology*, **2020**, 180, 114189	6	3
77	Pharmacokinetics of anticoagulants apixaban, dabigatran, edoxaban and rivaroxaban in elderly Japanese patients with atrial fibrillation treated in one general hospital. *Xenobiotica*, **2019**, 49, 1001-1006	2	3
76	Liquid chromatography-tandem mass spectrometry analysis of oxidation of 2', 3', 4'and 6-hydroxyflavanones by human cytochrome P450 enzymes. *Xenobiotica*, **2021**, 51, 139-154	2	3
75	Plasma and hepatic concentrations of acetaminophen and its primary conjugates after oral administrations determined in experimental animals and humans and extrapolated by pharmacokinetic modeling. *Xenobiotica*, **2021**, 51, 316-323	2	3
74	In vivo drug interactions of itopride and trimethylamine mediated by flavin-containing monooxygenase 3 in humanized-liver mice. *Drug Metabolism and Pharmacokinetics*, **2021**, 37, 100369	2.2	3
73	Human total clearance values and volumes of distribution of typical human cytochrome P450 2C9/19 substrates predicted by single-species allometric scaling using pharmacokinetic data sets from common marmosets genotyped for. *Xenobiotica*, **2021**, 51, 479-493	2	3
72	Pharmacokinetics of duloxetine self-administered in overdose with quetiapine and other antipsychotic drugs in a Japanese patient admitted to hospital. *Journal of Pharmaceutical Health Care and Sciences*, **2021**, 7, 6	1.8	3
71	Dihydrocodeine Overdoses in a Neonate and in a 14-year-old Girl Who Were Both Genotyped as Cytochrome P450 2D6*1/*10-*36: Comparing Developmental Ages and Drug Monitoring Data With the Results of Pharmacokinetic Modeling. *Therapeutic Drug Monitoring*, **2018**, 40, 162-165	3.2	3

70	Feasibility of physiologically based pharmacokinetic simulations for assessing pediatric patients after accidental drug ingestion: A case study of a 1.4-year-old girl who ingested alprazolam. *Drug Metabolism and Pharmacokinetics*, **2021**, 39, 100394	2.2	3
69	Cytochrome P450-dependent drug oxidation activities and their expression levels in liver microsomes of chimeric TK-NOG mice with humanized livers.. *Drug Metabolism and Pharmacokinetics*, **2022**, 44, 100454	2.2	3
68	Molecular cloning and tissue distribution of a novel marmoset ABC transporter. *Biopharmaceutics and Drug Disposition*, **2018**, 39, 59-63	1.7	2
67	In vivo multiple metabolic pathways for a novel G protein-coupled receptor 119 agonist DS-8500a in rats: involvement of the 1,2,4-oxadiazole ring-opening reductive reaction in livers under anaerobic conditions. *Xenobiotica*, **2019**, 49, 961-969	2	2
66	O I.4 Roles of human cytochrome P450s 1A1, 1A2, 1B1, 2E1, and 3A4/5/7 in the activation of environmental procarcinogens and promutagens. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **1997**, 379, S6	3.3	2
65	Novel nonsynonymous polymorphisms of the CYP1A1 gene in Japanese. *Drug Metabolism and Pharmacokinetics*, **2003**, 18, 218-21	2.2	2
64	Aflatoxin B1 oxidation by human cytochrome P450s. *Journal of Toxicological Sciences*, **1998**, 23 Suppl 2, 132-5	1.9	2
63	Genotoxicity of carcinogenic N-nitrosopropylamine derivatives in the hepatocyte primary culture/DNA-repair test. *Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis*, **1985**, 144, 197-202		2
62	Roles of human cytochrome P450 1A2 in coumarin 3,4-epoxidation mediated by untreated hepatocytes and by those metabolically inactivated with furafylline in previously transplanted chimeric mice. *Journal of Toxicological Sciences*, **2021**, 46, 525-530	1.9	2
61	Pharmacokinetics of primary metabolites 5-hydroxythalidomide and 5G-hydroxythalidomide formed after oral administration of thalidomide in the rabbit, a thalidomide-sensitive species. *Journal of Toxicological Sciences*, **2021**, 46, 553-560	1.9	2
60	Drug-oxidizing and conjugating non-cytochrome P450 (non-P450) enzymes in cynomolgus monkeys and common marmosets as preclinical models for humans.. *Biochemical Pharmacology*, **2021**, 197, 114887	6	2
59	Effects of Meat Intake Frequency and Polymorphic Cytochrome P450 2A6 Activity on Individual Colorectal Tumour Risk in a Japanese Cohort. *Journal of Cancer Therapy*, **2017**, 08, 645-652	0.2	2
58	Extrapolation of Hepatic Concentrations of Industrial Chemicals Using Pharmacokinetic Models to Predict Hepatotoxicity. *Toxicological Research*, **2019**, 35, 295-301	3.7	2
57	Species, Ethnic, and Individual Differences in Human Drug-Metabolizing Cytochrome P450 Enzymes **2014**, 293-305		2
56	Plasma concentrations of pemafibrate with co-administered drugs predicted by physiologically based pharmacokinetic modeling in virtual populations with renal/hepatic impairment. *Xenobiotica*, **2020**, 50, 1023-1031	2	2
55	An Updated Prediction Method for Volumes of Systemic Circulation of 323 Disparate Chemicals for Use in Physiologically Based Pharmacokinetic Models to Estimate Plasma and Tissue Concentrations after Oral Doses in Rats. *Chemical Research in Toxicology*, **2021**, 34, 2180-2183	4	2
54	Pharmacokinetics of loxoprofen in a self-administered overdose in a Japanese patient admitted to hospital. *Journal of Pharmaceutical Health Care and Sciences*, **2021**, 7, 33	1.8	2
53	Different substrate elimination rates of model drugs pH-dependently mediated by flavin-containing monooxygenases and cytochromes P450 in human liver microsomes. *Drug Metabolism and Pharmacokinetics*, **2021**, 40, 100412	2.2	2

52	Metabolic profiles for the pyrrolizidine alkaloid neopetasitenine and its metabolite petasitenine in humans extrapolated from rat in vivo and in vitro data sets using a simplified physiologically based pharmacokinetic model. *Journal of Toxicological Sciences*, **2021**, 46, 391-399	1.9	2
51	Immunoglobulin-A and -G responses against virus-like particles (VLP) of human papillomavirus type 16 in women with cervical cancer and cervical intra-epithelial lesions **1998**, 75, 529		2
50	Novel variants in outer protein surface of flavin-containing monooxygenase 3 found in an Argentinian case with impaired capacity for trimethylamine N-oxygenation. *Drug Metabolism and Pharmacokinetics*, **2020**, 35, 383-388	2.2	1
49	Interleukin-1 and tumor necrosis factor- affect cytochrome P450 expression in cynomolgus macaque hepatocytes. *Drug Metabolism and Pharmacokinetics*, **2020**, 35, 341-343	2.2	1
48	Hepatic expression of cytochrome P450 enzymes in non-human primate species. *Journal of Medical Primatology*, **2017**, 46, 347-351	0.7	1
47	Cytochrome P450 metabolic activities in the small intestine of cynomolgus macaques bred in Cambodia, China, and Indonesia. *Drug Metabolism and Pharmacokinetics*, **2013**, 28, 510-3	2.2	1
46	Cytochrome P450 2A6 Phenotyping Based on Dietary Caffeine Intake in a Japanese Population of Non-smokers. *Drug Metabolism Letters*, **2012**, 6, 67-72	2.1	1
45	Evaluation of cytotoxic potential of cored soft contact lenses with adsorbed active ingredients from over-the-counter eye drops. *Journal of Toxicological Sciences*, **2012**, 37, 639-43	1.9	1
44	Different Effects of Polymorphic Flavin-Containing Monooxygenase 3 and Cytochrome P450 2A6 Activities on an Index of Arteriosclerosis as a Lifestyle-Related Disease in a General Population in Japan. *Current Drug Metabolism*, **2020**, 21, 1161-1164	3.5	1
43	A case of adenoid cystic carcinoma arising at the circumvallate papilla of the tongue.. *Nihon Koku Geka Gakkai Zasshi*, **2000**, 46, 775-777	0.1	1
42	Pharmacokinetics of caffeine self-administered in overdose in a Japanese patient admitted to hospital. *Journal of Pharmaceutical Health Care and Sciences*, **2021**, 7, 36	1.8	1
41	Expression levels of microRNAs that are potential cytochrome P450 regulators in cynomolgus macaques. *Xenobiotica*, **2020**, 50, 747-752	2	1
40	Cloning and tissue expression of cytochrome P450 2S1, 4V2, 7A1, 7B1, 8B1, 24A1, 26A1, 26C1, 27A1, 39A1, and 51A1 in marmosets. *Drug Metabolism and Pharmacokinetics*, **2020**, 35, 244-247	2.2	1
39	Human plasma concentration-time profiles of troglitazone and troglitazone sulfate simulated by in vivo experiments with chimeric mice with humanized livers and semi-physiological pharmacokinetic modeling. *Drug Metabolism and Pharmacokinetics*, **2020**, 35, 505-514	2.2	1
38	Molecular cloning, sequence analysis, and tissue distribution of marmoset monoamine oxidases A and B. *Drug Metabolism and Pharmacokinetics*, **2020**, 35, 479-482	2.2	1
37	Molecular characterization of UDP-glucuronosyltransferases 3A and 8A in cynomolgus macaques. *Drug Metabolism and Pharmacokinetics*, **2020**, 35, 397-400	2.2	1
36	Trimethylamine N-oxygenation in cynomolgus macaques genotyped for flavin-containing monooxygenase 3 (FMO3). *Drug Metabolism and Pharmacokinetics*, **2020**, 35, 571-573	2.2	1
35	Hepatotoxicological potential of -toluic acid in humanised-liver mice investigated using simplified physiologically based pharmacokinetic models. *Xenobiotica*, **2021**, 51, 636-642	2	1

34	Differences in Hydrolase Activities in the Liver and Small Intestine between Marmosets and Humans. *Drug Metabolism and Disposition*, **2021**, 49, 718-728	4	1
33	Genetic variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects identified by phenotyping for trimethylaminuria and found in a database of genome resources. *Drug Metabolism and Pharmacokinetics*, **2021**, 38, 100387	2.2	1
32	Identification of putative substrates for cynomolgus monkey cytochrome P450 2C8 by substrate depletion assays with 22 human P450 substrates and inhibitors. *Biopharmaceutics and Drug Disposition*, **2016**, 37, 310-3	1.7	1
31	Expression and metabolic activity of flavin-containing monooxygenase 1 in cynomolgus macaque kidney. *Journal of Medical Primatology*, **2019**, 48, 51-53	0.7	1
30	Genetic variants of UDP-glucuronosyltransferases 1A1, 1A6, and 1A9 in cynomolgus and rhesus macaques. *Xenobiotica*, **2021**, 51, 115-121	2	1
29	Genetic variants of aldehyde oxidase (AOX) 1 in cynomolgus and rhesus macaques. *Xenobiotica*, **2021**, 51, 494-499	2	1
28	Differences in Pharmacokinetics and Haematotoxicities of Aniline and Its Dimethyl Derivatives Orally Administered in Rats. *Biological and Pharmaceutical Bulletin*, **2021**, 44, 1775-1780	2.3	1
27	Roles of cytochrome P450 2A6 in the oxidation of flavone, 4′-hydroxyflavone, and 4′-, 3′- and 2′-methoxyflavones by human liver microsomes. *Xenobiotica*, **2021**, 51, 995-1009	2	1
26	Oxidative metabolism and pharmacokinetics of the EGFR inhibitor BIBX1382 in chimeric NOG-TKm30 mice transplanted with human hepatocytes. *Drug Metabolism and Pharmacokinetics*, **2021**, 41, 100419	2.2	1
25	A series of simple detection systems for genetic variants of flavin-containing monooxygenase 3 (FMO3) with impaired function in Japanese subjects. *Drug Metabolism and Pharmacokinetics*, **2021**, 41, 100420	2.2	1
24	Prediction of permeability across intestinal cell monolayers for 219 disparate chemicals using in vitro experimental coefficients in a pH gradient system and in silico analyses by trivariate linear regressions and machine learning. *Biochemical Pharmacology*, **2021**, 192, 114749	6	1
23	Probe drug T-1032 N-oxygenation mediated by cytochrome P450 3A5 in human hepatocytes in vitro and in humanized-liver mice in vivo.. *Drug Metabolism and Pharmacokinetics*, **2022**, 44, 100453	2.2	1
22	Imaging Mass Spectrometry (IMS) for drug discovery and development survey: Results on methods, applications and regulatory compliance.. *Drug Metabolism and Pharmacokinetics*, **2021**, 43, 100438	2.2	0
21	Effects of polymorphic cytochrome P450 2A6 genotypes on chemoprevention against colorectal tumors in single Japanese cohort using daily low-dose aspirin: insights into future personalized treatments. *Journal of Pharmaceutical Health Care and Sciences*, **2021**, 7, 26	1.8	0
20	Predictability of human pharmacokinetics of diisononyl phthalate (DINP) using chimeric mice with humanized liver. *Xenobiotica*, **2019**, 49, 1311-1322	2	0
19	UDP-glucuronosyltransferase 1A4-mediated N2-glucuronidation is the major metabolic pathway of lamotrigine in chimeric NOG-TKm30 mice with humanised-livers. *Xenobiotica*, **2021**, 51, 1146-1154	2	0
18	Comparison of mouse and human cytochrome P450 mediated-drug metabolizing activities in hepatic and extrahepatic microsomes.. *Xenobiotica*, **2022**, 1-28	2	0
17	CYP2C76 deficiency is embryonic lethal in cynomolgus macaques: The potential role of CYP2C76 in early embryogenesis. *Drug Metabolism and Pharmacokinetics*, **2017**, 32, 112-115	2.2	

16	Molecular cloning and tissue distribution of marmoset thiopurine S-methyltransferase. *Drug Metabolism and Pharmacokinetics*, **2020**, 35, 475-478	2.2
15	mRNA levels of drug-metabolizing enzymes in 11 brain regions of cynomolgus macaques. *Drug Metabolism and Pharmacokinetics*, **2020**, 35, 248-252	2.2
14	Polymorphisms of cytochrome P450 2B6 (CYP2B6) in cynomolgus and rhesus macaques. *Journal of Medical Primatology*, **2018**, 47, 232	0.7
13	ADME of Anticancer Drugs **2012**, 1	
12	Systematic identification and characterization of cynomolgus macaque solute carrier transporters.. *Drug Metabolism and Pharmacokinetics*, **2021**, 43, 100437	2.2
11	Cloning and tissue expression of ATP-binding cassette transporters in cynomolgus macaques.. *Drug Metabolism and Pharmacokinetics*, **2021**, 42, 100431	2.2
10	DELINEATION OF THE SURGICAL MARGINS OF SOFT TISSUE IN THE SURGICAL PROCEDURE FOR GINGIVAL CANCER OF MANDIBLE, BASED ON THE DEPTH OF INVASION. *Japanese Jornal of Head and Neck Cancer*, **2001**, 27, 38-43	
9	OMEPRAZOLE HYDROXYLATION BY CYP2C19 AND CYP3A4: PREDICTION TOWARDS HUMAN LIVER ACTIVITIES USING THE DATA OF RECOMBINANT P450 ENZYMES. *Drug Metabolism and Pharmacokinetics*, **1997**, 12, 120-121	
8	Drug Interactions Mediated by Drug-Metabolizing Enzymes. *Japanese Journal of Clinical Pharmacology and Therapeutics*, **2013**, 44, 470-472	0
7	Clinical use and evaluation of nonsteroid analgesic antiinflammatory agent, 16091 R. P.(Metiazinic acid) in oral surgery. *Nihon Koku Geka Gakkai Zasshi*, **1974**, 20, 501-511	0.1
6	Regional distributions of UDP-glucuronosyltransferase activities toward estradiol and serotonin in the liver and small intestine of cynomolgus macaques. *Drug Metabolism and Pharmacokinetics*, **2020**, 35, 401-404	2.2
5	Modelled plasma concentrations of pemafibrate with co-administered typical cytochrome P450 inhibitors clopidogrel, fluconazole or clarithromycin predicted by physiologically based pharmacokinetic modelling in virtual populations. *Xenobiotica*, **2020**, 50, 1413-1422	2
4	Evaluation of domain of unknown function 1220 (DUF1220) for detection of human genome by quantitative polymerase chain reaction: Potential use in assessing the biodistribution of transplanted therapeutic human cells. *Drug Metabolism and Pharmacokinetics*, **2021**, 38, 100366	2.2
3	Cloning, sequence analysis, and tissue expression of marmoset paraoxonase 1. *Drug Metabolism and Pharmacokinetics*, **2021**, 39, 100398	2.2
2	Oxidation of 3′-methoxyflavone, 4′-methoxyflavone, and 3′,4′-dimethoxyflavone and their derivatives having 5,7-dihydroxyl moieties by human cytochromes P450 1B1 and 2A13.. *Xenobiotica*, **2022**, 1-12	2
1	Polymorphic cytochromes P450 in non-human primates. *Advances in Pharmacology*, **2022**,	5.7